




Rec'd PCT/PTO 27 APR 2005
PCT/GB 2003 / 0 0 4 6 8 5



INVESTOR IN PEOPLE

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ




BEST AVAILABLE COPY

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.




PRIORITY DOCUMENT
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH
RULE 17.1(a) OR (b)

Signed

Stephen Hordley

Dated

12 November 2003



The Patent Office

1/77

Request for grant of a patent

Read the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form.

The Patent Office

Cardiff Road
Newport
Gwent NP9 1RH

Your reference

T1567PV2

13JUN03 E814671-1 002639
P01/7700 0.00-0313646.2

Patent application number

(The Patent Office will fill in this part)

0313646.2

Full name, address and postcode of the or of each applicant (underline all surnames)

Merck Sharp & Dohme Limited
Hertford Road, Hoddesdon
Hertfordshire EN11 9BU
United Kingdom

Patents ADP number (if you know it)

00597799001✓

If the applicant is a corporate body, give the country/state of its incorporation

United Kingdom

Title of the invention

Therapeutic agents

Name of your agent (if you have one)

Dr. J. Thompson

"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)

Merck & Co., Inc.
European Patent Department
Terlings Park
Eastwick Road
Harlow
Essex CM20 2QR

Patents ADP number (if you know it)

4392742002✓

If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number

Country

Priority Application number
(if you know it)

Date of filing
(day/month/year)

If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application

Date of filing
(day/month/year)

Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if:

Yes

- a) any applicant named in part 3 is not an inventor, or
 - b) there is an inventor who is not named as an applicant, or
 - c) any named applicant is a corporate body.
- See note (d))

Patents Form 1/77

2. Enter the number of sheets for any of the following items you are filing with this form.
Do not count copies of the same document

Continuation sheets of this form	0
Description	52 DL
Claim(s)	0
Abstract	0
Drawing(s)	0

0. If you are also filing any of the following, state how many against each item.

Priority documents	-
Translations of priority documents	-
Statement of inventorship and right to grant of a patent (Patents Form 7/77)	-
Request for preliminary examination and search (Patents Form 9/77)	-
Request for substantive examination (Patents Form 10/77)	-
Any other documents (please specify)	-

1. I/We request the grant of a patent on the basis of this application.

Signature	Date
Dr. J. Thompson	11 June 2003

2. Name and daytime telephone number of person to contact in the United Kingdom
- | | |
|-----------------|--------------|
| Dr. J. Thompson | 01279 440172 |
|-----------------|--------------|

Warning
After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes
If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.

Write your answers in capital letters using black ink or you may type them.

If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.

If you have answered 'Yes' Patents Form 7/77 will need to be filed.

Once you have filled in the form you must remember to sign and date it.

For details of the fee and ways to pay please contact the Patent Office.

THERAPEUTIC AGENTS

The present invention relates to a class of substituted imidazo-
pyrazinone derivatives and to their use in therapy. More particularly, this
5 invention is concerned with imidazo[1,2-*a*]pyrazin-8-one analogues which
are substituted in the 3-position by a substituted phenyl ring. These
compounds are ligands for GABA_A receptors and are therefore useful in
the therapy of deleterious neurological complaints.

Receptors for the major inhibitory neurotransmitter, gamma-
10 aminobutyric acid (GABA), are divided into two main classes: (1) GABA_A
receptors, which are members of the ligand-gated ion channel superfamily;
and (2) GABA_B receptors, which may be members of the G-protein linked
receptor superfamily. Since the first cDNAs encoding individual GABA_A
receptor subunits were cloned the number of known members of the
15 mammalian family has grown to include at least six α subunits, four β
subunits, three γ subunits, one δ subunit, one ϵ subunit and two ρ
subunits.

Although knowledge of the diversity of the GABA_A receptor gene
family represents a huge step forward in our understanding of this ligand-
20 gated ion channel, insight into the extent of subtype diversity is still at an
early stage. It has been indicated that an α subunit, a β subunit and a γ
subunit constitute the minimum requirement for forming a fully
functional GABA_A receptor expressed by transiently transfecting cDNAs
into cells. As indicated above, δ , ϵ and ρ subunits also exist, but are
25 present only to a minor extent in GABA_A receptor populations.

Studies of receptor size and visualisation by electron microscopy
conclude that, like other members of the ligand-gated ion channel family,
the native GABA_A receptor exists in pentameric form. The selection of at
least one α , one β and one γ subunit from a repertoire of seventeen allows
30 for the possible existence of more than 10,000 pentameric subunit
combinations. Moreover, this calculation overlooks the additional

permutations that would be possible if the arrangement of subunits around the ion channel had no constraints (i.e. there could be 120 possible variants for a receptor composed of five different subunits).

5 Receptor subtype assemblies which do exist include, amongst many others, $\alpha 1\beta 2\gamma 2$, $\alpha 2\beta \gamma 1$, $\alpha 2\beta 2/3\gamma 2$, $\alpha 3\beta \gamma 2/3$, $\alpha 4\beta \delta$, $\alpha 5\beta 3\gamma 2/3$, $\alpha 6\beta \gamma 2$ and $\alpha 6\beta \delta$. Subtype assemblies containing an $\alpha 1$ subunit are present in most areas of the brain and are thought to account for over 40% of GABA_A receptors in the rat. Subtype assemblies containing $\alpha 2$ and $\alpha 3$ subunits respectively are thought to account for about 25% and 17% of GABA_A receptors in the
10 rat. Subtype assemblies containing an $\alpha 5$ subunit are expressed predominantly in the hippocampus and cortex and are thought to represent about 4% of GABA_A receptors in the rat.

 A characteristic property of all known GABA_A receptors is the presence of a number of modulatory sites, one of which is the
15 benzodiazepine (BZ) binding site. The BZ binding site is the most explored of the GABA_A receptor modulatory sites, and is the site through which anxiolytic drugs such as diazepam and temazepam exert their effect. Before the cloning of the GABA_A receptor gene family, the benzodiazepine binding site was historically subdivided into two subtypes, BZ1 and BZ2,
20 on the basis of radioligand binding studies. The BZ1 subtype has been shown to be pharmacologically equivalent to a GABA_A receptor comprising the $\alpha 1$ subunit in combination with a β subunit and $\gamma 2$. This is the most abundant GABA_A receptor subtype, and is believed to represent almost half of all GABA_A receptors in the brain.

25 Two other major populations are the $\alpha 2\beta \gamma 2$ and $\alpha 3\beta \gamma 2/3$ subtypes. Together these constitute approximately a further 35% of the total GABA_A receptor repertoire. Pharmacologically this combination appears to be equivalent to the BZ2 subtype as defined previously by radioligand binding, although the BZ2 subtype may also include certain $\alpha 5$ -containing
30 subtype assemblies. The physiological role of these subtypes has hitherto

been unclear because no sufficiently selective agonists or antagonists were known.

It is now believed that agents acting as BZ agonists at $\alpha 1\beta\gamma 2$, $\alpha 2\beta\gamma 2$ or $\alpha 3\beta\gamma 2$ subtypes will possess desirable anxiolytic properties. Compounds which are modulators of the benzodiazepine binding site of the GABA_A receptor by acting as BZ agonists are referred to hereinafter as "GABA_A receptor agonists". The $\alpha 1$ -selective GABA_A receptor agonists alpidem and zolpidem are clinically prescribed as hypnotic agents, suggesting that at least some of the sedation associated with known anxiolytic drugs which act at the BZ1 binding site is mediated through GABA_A receptors containing the $\alpha 1$ subunit. Accordingly, it is considered that GABA_A receptor agonists which interact more favourably with the $\alpha 2$ and/or $\alpha 3$ subunit than with $\alpha 1$ will be effective in the treatment of anxiety with a reduced propensity to cause sedation. Moreover, agents which are inverse agonists of the $\alpha 5$ subunit are likely to be beneficial in enhancing cognition, for example in subjects suffering from dementing conditions such as Alzheimer's disease. Also, agents which are antagonists or inverse agonists at $\alpha 1$ might be employed to reverse sedation or hypnosis caused by $\alpha 1$ agonists.

The compounds of the present invention, being selective ligands for GABA_A receptors, are therefore of use in the treatment and/or prevention of a variety of disorders of the central nervous system. Such disorders include anxiety disorders, such as panic disorder with or without agoraphobia, agoraphobia without history of panic disorder, animal and other phobias including social phobias, obsessive-compulsive disorder, stress disorders including post-traumatic and acute stress disorder, and generalized or substance-induced anxiety disorder; neuroses; convulsions; migraine; depressive or bipolar disorders, for example single-episode or recurrent major depressive disorder, dysthymic disorder, bipolar I and bipolar II manic disorders, and cyclothymic disorder; psychotic disorders including schizophrenia; neurodegeneration arising from cerebral

ischemia; attention deficit hyperactivity disorder; Tourette's syndrome; speech disorders, including stuttering; and disorders of circadian rhythm, e.g. in subjects suffering from the effects of jet lag or shift work.

Further disorders for which selective ligands for GABA_A receptors may be of benefit include pain and nociception; emesis, including acute, delayed and anticipatory emesis, in particular emesis induced by chemotherapy or radiation, as well as motion sickness, and post-operative nausea and vomiting; eating disorders including anorexia nervosa and bulimia nervosa; premenstrual syndrome; muscle spasm or spasticity, e.g. in paraplegic patients; hearing disorders, including tinnitus and age-related hearing impairment; urinary incontinence; and the effects of substance abuse or dependency, including alcohol withdrawal. Selective ligands for GABA_A receptors may be beneficial in enhancing cognition, for example in subjects suffering from dementing conditions such as Alzheimer's disease; and may also be effective as pre-medication prior to anaesthesia or minor procedures such as endoscopy, including gastric endoscopy.

In addition, the compounds in accordance with the present invention may be useful as radioligands in assays for detecting compounds capable of binding to the human GABA_A receptor.


WO 02/10170 describes a class of 3-phenylimidazo[1,2-*a*]pyrazine derivatives which are stated to be selective ligands for GABA_A receptors, in particular having high affinity for the $\alpha 2$ and/or $\alpha 3$ subunit thereof, and accordingly to be of benefit in the treatment and/or prevention of neurological disorders, including anxiety and convulsions. However, there is no disclosure nor any suggestion in that publication of therapeutic agents based on a 7-substituted imidazo[1,2-*a*]pyrazin-8-one ring system.

The present invention provides a class of imidazo-pyrazinone derivatives which possess desirable binding properties at various GABA_A receptor subtypes. The compounds in accordance with the present invention have good affinity as ligands for the $\alpha 2$ and/or $\alpha 3$ and/or $\alpha 5$

subunit of the human GABA_A receptor. The compounds of this invention may interact more favourably with the $\alpha 2$ and/or $\alpha 3$ subunit than with the $\alpha 1$ subunit; and/or may interact more favourably with the $\alpha 5$ subunit than with the $\alpha 1$ subunit.

5 The compounds of the present invention are GABA_A receptor subtype ligands having a binding affinity (K_i) for the $\alpha 2$ and/or $\alpha 3$ and/or $\alpha 5$ subunit, as measured in the assay described hereinbelow, of 200 nM or less, typically of 100 nM or less, and ideally of 20 nM or less. The compounds in accordance with this invention may possess at least a 2-fold, 10 suitably at least a 5-fold, and advantageously at least a 10-fold, selective affinity for the $\alpha 2$ and/or $\alpha 3$ and/or $\alpha 5$ subunit relative to the $\alpha 1$ subunit. However, compounds which are not selective in terms of their binding affinity for the $\alpha 2$ and/or $\alpha 3$ and/or $\alpha 5$ subunit relative to the $\alpha 1$ subunit are also encompassed within the scope of the present invention; such 15 compounds will desirably exhibit functional selectivity in terms of zero or weak (positive or negative) efficacy at the $\alpha 1$ subunit and (i) a full or partial agonist profile at the $\alpha 2$ and/or $\alpha 3$ subunit, and/or (ii) an inverse agonist profile at the $\alpha 5$ subunit.

20 The present invention provides a compound of formula I, or a pharmaceutically acceptable salt thereof:



(I)

wherein

25 -U-V- represents -CH=CH- or -CH₂-CH₂-;

X¹ represents hydrogen, halogen, C₁₋₆ alkyl, trifluoromethyl or C₁₋₆ alkoxy;

X² represents hydrogen or halogen;

Y represents a chemical bond, an oxygen atom, or a -NH- or -OCH₂- linkage;

Z represents an optionally substituted aryl or heteroaryl group;

R¹ represents hydrocarbon, a heterocyclic group, trifluoromethyl, -SO₂R^a, -SO₂NR^aR^b, -COR^a, -CO₂R^a or -CONR^aR^b; and

R^a and R^b independently represent hydrogen, hydrocarbon or a heterocyclic group.

The present invention also provides a compound of formula I as depicted above, or a pharmaceutically acceptable salt thereof, wherein

-U-V- represents -CH=CH-;

Y represents a chemical bond, an oxygen atom, or a -NH- linkage;

and

X¹, X², Z and R¹ are as defined above.

The aryl or heteroaryl group Z in the compounds of formula I above may be unsubstituted, or substituted by one or more substituents.

Typically, the group Z will be unsubstituted, or substituted by one or two substituents. Suitably, the group Z is unsubstituted or monosubstituted.

Typical substituents on the group Z include halogen, cyano, nitro, C₁₋₆ alkyl, hydroxy, C₁₋₆ alkoxy, oxy, C₁₋₆ alkylsulphonyl, amino, aminocarbonyl, formyl, C₂₋₆ alkoxy carbonyl and -CR^a=NOR^b, wherein R^a and R^b are as defined above.

For use in medicine, the salts of the compounds of formula I will be pharmaceutically acceptable salts. Other salts may, however, be useful in the preparation of the compounds according to the invention or of their pharmaceutically acceptable salts. Suitable pharmaceutically acceptable salts of the compounds of this invention include acid addition salts which may, for example, be formed by mixing a solution of the compound according to the invention with a solution of a pharmaceutically acceptable

acid such as hydrochloric acid, sulphuric acid, methanesulphonic acid, fumaric acid, maleic acid, succinic acid, acetic acid, benzoic acid, oxalic acid, citric acid, tartaric acid, carbonic acid or phosphoric acid.

Furthermore, where the compounds of the invention carry an acidic moiety, suitable pharmaceutically acceptable salts thereof may include
5 alkali metal salts, e.g. sodium or potassium salts; alkaline earth metal salts, e.g. calcium or magnesium salts; and salts formed with suitable organic ligands, e.g. quaternary ammonium salts.

The term "hydrocarbon" as used herein includes straight-chained,
10 branched and cyclic groups containing up to 18 carbon atoms, suitably up to 15 carbon atoms, and conveniently up to 12 carbon atoms. Suitable hydrocarbon groups include C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkyl(C₁₋₆)alkyl, indanyl, aryl and aryl(C₁₋₆)alkyl.

The expression "a heterocyclic group" as used herein includes cyclic
15 groups containing up to 18 carbon atoms and at least one heteroatom preferably selected from oxygen, nitrogen and sulphur. The heterocyclic group suitably contains up to 15 carbon atoms and conveniently up to 12 carbon atoms, and is preferably linked through carbon. Examples of suitable heterocyclic groups include C₃₋₇ heterocycloalkyl, C₃₋₇
20 heterocycloalkyl(C₁₋₆)alkyl, heteroaryl and heteroaryl(C₁₋₆)alkyl groups.

Suitable alkyl groups include straight-chained and branched alkyl groups containing from 1 to 6 carbon atoms. Typical examples include methyl and ethyl groups, and straight-chained or branched propyl, butyl and pentyl groups. Particular alkyl groups are methyl, ethyl, *n*-propyl,
25 isopropyl, isobutyl, *tert*-butyl and 2,2-dimethylpropyl. Derived expressions such as "C₁₋₆ alkoxy", "C₁₋₆ alkylamino" and "C₁₋₆ alkylsulphonyl" are to be construed accordingly.

Suitable alkenyl groups include straight-chained and branched alkenyl groups containing from 2 to 6 carbon atoms. Typical examples
30 include vinyl, allyl and dimethylallyl groups.

Suitable alkynyl groups include straight-chained and branched alkynyl groups containing from 2 to 6 carbon atoms. Typical examples include ethynyl and propargyl groups.

5 Suitable cycloalkyl groups include groups containing from 3 to 7 carbon atoms. Particular cycloalkyl groups are cyclopropyl and cyclohexyl.

Typical examples of C₃₋₇ cycloalkyl(C₁₋₆)alkyl groups include cyclopropylmethyl, cyclohexylmethyl and cyclohexylethyl.

Particular indanyl groups include indan-1-yl and indan-2-yl.

10 Particular aryl groups include phenyl and naphthyl, preferably phenyl.

Particular aryl(C₁₋₆)alkyl groups include benzyl, phenylethyl, phenylpropyl and naphthylmethyl.

Suitable heterocycloalkyl groups include azetidiny, pyrrolidiny, piperidiny, piperaziny, morpholiny and thiomorpholiny groups.

15 Suitable heteroaryl groups include pyridiny, quinoliny, isoquinoliny, pyridaziny, pyrimidiny, pyraziny, furyl, benzofuryl, dibenzofuryl, thienyl, benzthienyl, pyrrolyl, indolyl, pyrazolyl, indazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, imidazolyl, benzimidazolyl, oxadiazolyl, thiadiazolyl, triazolyl and tetrazolyl groups.

20 The expression "heteroaryl(C₁₋₆)alkyl" as used herein includes furylmethyl, furylethyl, thienylmethyl, thienylethyl, oxazolylmethyl, oxazolyethyl, thiazolylmethyl, thiazolyethyl, imidazolylmethyl, imidazolyethyl, oxadiazolylmethyl, oxadiazolyethyl, thiadiazolylmethyl, thiadiazolyethyl, triazolylmethyl, triazolyethyl, tetrazolylmethyl, 25 tetrazolyethyl, pyridinylmethyl, pyridinyethyl, pyrimidinylmethyl, pyrazinylmethyl, quinolinylmethyl and isoquinolinylmethyl.

The hydrocarbon and heterocyclic groups may in turn be optionally substituted by one or more groups selected from C₁₋₆ alkyl, adamantyl, phenyl, halogen, C₁₋₆ haloalkyl, C₁₋₆ aminoalkyl, trifluoromethyl, hydroxy, 30 C₁₋₆ alkoxy, aryloxy, keto, C₁₋₃ alkylenedioxy, nitro, cyano, carboxy, C₂₋₆ alkoxycarbonyl, C₂₋₆ alkoxycarbonyl(C₁₋₆)alkyl, C₂₋₆ alkylcarbonyloxy,

arylcarbonyloxy, aminocarbonyloxy, C₂₋₆ alkylcarbonyl, arylcarbonyl, C₁₋₆ alkylthio, C₁₋₆ alkylsulphanyl, C₁₋₆ alkylsulphonyl, arylsulphonyl, -NR^vR^w, -NR^vCOR^w, -NR^vCO₂R^w, -NR^vSO₂R^w, -CH₂NR^vSO₂R^w, -NHCONR^vR^w, -CONR^vR^w, -SO₂NR^vR^w and -CH₂SO₂NR^vR^w, in which R^v and R^w independently represent hydrogen, C₁₋₆ alkyl, aryl or aryl(C₁₋₆)alkyl.

The term "halogen" as used herein includes fluorine, chlorine, bromine and iodine, especially fluoro or chloro.

Where the compounds according to the invention have at least one asymmetric centre, they may accordingly exist as enantiomers. Where the compounds according to the invention possess two or more asymmetric centres, they may additionally exist as diastereoisomers. It is to be understood that all such isomers and mixtures thereof in any proportion are encompassed within the scope of the present invention.

In one embodiment of the compounds according to the present invention, -U-V- represents -CH=CH-.

In another embodiment, -U-V- represents -CH₂-CH₂-.

Suitable values for the X¹ substituent include hydrogen, fluoro, chloro, methyl, trifluoromethyl and methoxy; in particular hydrogen or fluoro; and especially fluoro.

Suitably, X¹ represents halogen, C₁₋₆ alkyl, trifluoromethyl or C₁₋₆ alkoxy. Typical values of X¹ include fluoro, chloro, methyl, trifluoromethyl and methoxy, especially fluoro.

Typical values of X² include hydrogen and fluoro, especially hydrogen.

In a preferred embodiment, Y represents a chemical bond.

In an alternative embodiment, Y represents a -OCH₂- linkage.

In another embodiment, Y represents an oxygen atom.

In a further embodiment, Y represents a -NH- linkage.

Selected values for the substituent Z include phenyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, furyl, thienyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrrolyl, pyrazolyl, imidazolyl, oxadiazolyl,

thiadiazolyl, triazolyl and tetrazolyl, any of which groups may be optionally substituted by one or more substituents.

Particular values of Z include phenyl and triazolyl, either of which groups may be optionally substituted by one or more substituents.

5 In one favoured embodiment, Z represents an optionally substituted phenyl group, in particular monosubstituted or disubstituted phenyl. In another favoured embodiment, Z represents optionally substituted pyridinyl, especially unsubstituted, monosubstituted or disubstituted pyridin-2-yl, pyridin-3-yl or pyridin-4-yl.

10 Examples of suitable substituents on the group Z include fluoro, chloro, cyano, nitro, methyl, hydroxy, methoxy, oxy, methanesulphonyl, amino, aminocarbonyl, formyl, methoxycarbonyl and -CH=NOH.

Examples of typical substituents on the group Z include fluoro, chloro, cyano and methyl.

15 Examples of particular substituents on the group Z include fluoro and cyano, especially cyano.

Detailed values of Z include cyanophenyl, (cyano)(fluoro)phenyl, (chloro)(cyano)phenyl, nitrophenyl, methoxyphenyl, methanesulphonyl-phenyl, pyridinyl, fluoro-pyridinyl, difluoro-pyridinyl, (amino)(chloro)pyridinyl, cyano-pyridinyl, methyl-pyridinyl, hydroxy-pyridinyl, methoxy-pyridinyl, oxy-pyridinyl, aminocarbonyl-pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, cyano-thienyl, aminocarbonyl-thienyl, formyl-thienyl, methoxycarbonyl-thienyl, thienyl-CH=NOH, thiazolyl, isothiazolyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl and methyl-
25 tetrazolyl. Additionally, Z may represent methyl-triazolyl.

Specific values of Z include cyanophenyl, (cyano)(fluoro)phenyl, pyridinyl, difluoro-pyridinyl and cyano-pyridinyl.

Individual values of Z include cyanophenyl, (cyano)(fluoro)phenyl, (chloro)(cyano)phenyl and methyl-triazolyl.

30 In one embodiment, Z represents cyanophenyl, especially 2-cyanophenyl.

In another embodiment, Z represents (cyano)(fluoro)phenyl, especially 2-cyano-4-fluorophenyl. Alternative aspects of this embodiment include 2-cyano-5-fluorophenyl, 2-cyano-6-fluorophenyl and 4-cyano-2-fluorophenyl.

5 In an additional embodiment, Z represents (chloro)(cyano)phenyl, especially 3-chloro-4-cyanophenyl.

In a further embodiment, Z represents methyl-triazolyl, especially 1-methyl-1*H*-[1,2,3]triazol-4-yl or 2-methyl-2*H*-[1,2,4]triazol-3-yl.

Typically, R¹ represents hydrocarbon, a heterocyclic group, trifluoromethyl, -COR^a or -CO₂R^a.

Typical values of R^a include hydrogen and C₁₋₆ alkyl. Suitably, R^a represents hydrogen or methyl.

Typical values of R^b include hydrogen, C₁₋₆ alkyl, hydroxy(C₁₋₆)alkyl and di(C₁₋₆)alkylamino(C₁₋₆)alkyl. Suitably, R^b represents hydrogen, methyl, ethyl, hydroxyethyl or dimethylaminoethyl. Particular values of R^b include hydrogen, hydroxyethyl and dimethylaminoethyl, especially hydrogen or dimethylaminoethyl.

Suitable values of R¹ include C₁₋₆ alkyl, halo(C₁₋₆)alkyl, dihalo(C₁₋₆)alkyl, hydroxy(C₁₋₆)alkyl, dihydroxy(C₁₋₆)alkyl, C₁₋₆ alkoxy(C₁₋₆)alkyl, di(C₁₋₆)alkoxy(C₁₋₆)alkyl, cyano(C₁₋₆)alkyl, C₂₋₆ alkoxycarbonyl(C₁₋₆)alkyl, C₃₋₇ cycloalkyl, heteroaryl, C₁₋₆ alkyl-heteroaryl, heteroaryl(C₁₋₆)alkyl, trifluoromethyl, formyl, C₂₋₆ alkylcarbonyl and C₂₋₆ alkoxycarbonyl. Additional values of R¹ include trihalo(C₁₋₆)alkyl and (C₁₋₆)alkyl-heteroaryl(C₁₋₆)alkyl.

25 Representative values of R¹ include C₁₋₆ alkyl, halo(C₁₋₆)alkyl, dihalo(C₁₋₆)alkyl, hydroxy(C₁₋₆)alkyl and trifluoromethyl.

Particular values of R¹ include C₁₋₆ alkyl, halo(C₁₋₆)alkyl, dihalo(C₁₋₆)alkyl, trihalo(C₁₋₆)alkyl, heteroaryl(C₁₋₆)alkyl and (C₁₋₆)alkyl-heteroaryl(C₁₋₆)alkyl.


30 Individual values of R¹ include methyl, ethyl, fluoromethyl, difluoromethyl, hydroxymethyl, methoxymethyl, dimethoxymethyl,

hydroxyethyl (especially 2-hydroxyethyl), fluoroethyl (especially 2-fluoroethyl), difluoroethyl (especially 2,2-difluoroethyl), dimethoxyethyl (especially 2,2-dimethoxyethyl), isopropyl, hydroxypropyl (especially 2-hydroxyprop-2-yl), dihydroxypropyl (especially 1,2-dihydroxyprop-2-yl),
5 fluoropropyl (especially 2-fluoroprop-2-yl), cyanopropyl (especially 2-cyanoprop-2-yl), methoxycarbonylpropyl (especially 2-methoxycarbonylprop-2-yl), *tert*-butyl, hydroxybutyl (especially 1-hydroxy-2-methylprop-2-yl), cyclopropyl, pyridinyl, furyl, thienyl, oxazolyl, methylthiazolyl, methyloxadiazolyl, imidazolylmethyl, triazolylmethyl,
10 trifluoromethyl, formyl, acetyl and methoxycarbonyl. Additional values of R^1 include trifluoroethyl (especially 2,2,2-trifluoroethyl), methyl-triazolylmethyl (especially 2-methyl-2*H*-[1,2,4]triazol-3-ylmethyl) and pyridinylmethyl (especially pyridin-2-ylmethyl).

Specific values of R^1 include methyl, ethyl, fluoroethyl (especially 2-fluoroethyl), difluoroethyl (especially 2,2-difluoroethyl), trifluoroethyl (especially 2,2,2-trifluoroethyl), isopropyl, methyl-triazolylmethyl (especially 2-methyl-2*H*-[1,2,4]triazol-3-ylmethyl) and pyridinylmethyl (especially pyridin-2-ylmethyl).

In a first embodiment, R^1 represents methyl. In a second
20 embodiment, R^1 represents ethyl. In a third embodiment, R^1 represents fluoroethyl (especially 2-fluoroethyl). In a fourth embodiment, R^1 represents difluoroethyl (especially 2,2-difluoroethyl). In a fifth embodiment, R^1 represents trifluoroethyl (especially 2,2,2-trifluoroethyl). In a sixth embodiment, R^1 represents isopropyl. In a seventh embodiment,
25 R^1 represents methyl-triazolylmethyl (especially 2-methyl-2*H*-[1,2,4]triazol-3-ylmethyl). In an eighth embodiment, R^1 represents pyridinylmethyl (especially pyridin-2-ylmethyl). In a favoured embodiment, R^1 represents 2-hydroxyprop-2-yl. In another embodiment, R^1 represents 2-fluoroprop-2-yl. In an additional embodiment, R^1
30 represents trifluoromethyl.

A particular sub-class of compounds according to the invention is represented by the compounds of formula IIA, and pharmaceutically acceptable salts thereof:



(IIA)

wherein

U, V and Z are as defined above;

X¹¹ represents hydrogen, fluoro, chloro, methyl, trifluoromethyl or methoxy;

X¹² represents hydrogen or fluoro; and

R¹¹ represents C₁₋₆ alkyl, halo(C₁₋₆)alkyl, dihalo(C₁₋₆)alkyl, trihalo(C₁₋₆)alkyl, hydroxy(C₁₋₆)alkyl, dihydroxy(C₁₋₆)alkyl, C₁₋₆ alkoxy(C₁₋₆)alkyl, di(C₁₋₆)alkoxy(C₁₋₆)alkyl, cyano(C₁₋₆)alkyl, C₂₋₆ alkoxycarbonyl(C₁₋₆)alkyl, C₃₋₇ cycloalkyl, heteroaryl, C₁₋₆ alkyl-heteroaryl, heteroaryl(C₁₋₆)alkyl, (C₁₋₆)alkyl-heteroaryl(C₁₋₆)alkyl, trifluoromethyl, formyl, C₂₋₆ alkylcarbonyl or C₂₋₆ alkoxycarbonyl.

The present invention also provides a compound of formula IIA as depicted above, or a pharmaceutically acceptable salt thereof, wherein

-U-V- represents -CH=CH-;

R¹¹ represents C₁₋₆ alkyl, halo(C₁₋₆)alkyl, dihalo(C₁₋₆)alkyl, hydroxy(C₁₋₆)alkyl, dihydroxy(C₁₋₆)alkyl, C₁₋₆ alkoxy(C₁₋₆)alkyl, di(C₁₋₆)alkoxy(C₁₋₆)alkyl, cyano(C₁₋₆)alkyl, C₂₋₆ alkoxycarbonyl(C₁₋₆)alkyl, C₃₋₇ cycloalkyl, heteroaryl, C₁₋₆ alkyl-heteroaryl, heteroaryl(C₁₋₆)alkyl, trifluoromethyl, formyl, C₂₋₆ alkylcarbonyl or C₂₋₆ alkoxycarbonyl; and

Z, X¹¹ and X¹² are as defined above.

Suitable values of X¹¹ include hydrogen and fluoro, especially fluoro.

Typical values of X¹¹ include fluoro, chloro, methyl, trifluoromethyl and methoxy.

5 A particular value of X¹¹ is fluoro.

In a favoured embodiment, X¹² represents hydrogen. In another embodiment, X¹² represents fluoro.

Where R¹¹ represents heteroaryl, this group is suitably pyridinyl, furyl, thienyl or oxazolyl.

10 Where R¹¹ represents C₁₋₆ alkyl-heteroaryl, this group is suitably methylthiazolyl (e.g. 2-methylthiazol-5-yl) or methyloxadiazolyl (e.g. 3-methyl-[1,2,4]oxadiazol-5-yl).

Where R¹¹ represents heteroaryl(C₁₋₆)alkyl, this group is suitably imidazolylmethyl or triazolylmethyl. Additionally, the
15 heteroaryl(C₁₋₆)alkyl group R¹¹ may be pyridinylmethyl.

Representative values of R¹¹ include C₁₋₆ alkyl, halo(C₁₋₆)alkyl, dihalo(C₁₋₆)alkyl, hydroxy(C₁₋₆)alkyl and trifluoromethyl.

Particular values of R¹¹ include C₁₋₆ alkyl, halo(C₁₋₆)alkyl, dihalo(C₁₋₆)alkyl, trihalo(C₁₋₆)alkyl, heteroaryl(C₁₋₆)alkyl and (C₁₋₆)alkyl-
20 heteroaryl(C₁₋₆)alkyl.


Individual values of R¹¹ include methyl, ethyl, fluoromethyl, difluoromethyl, hydroxymethyl, methoxymethyl, dimethoxymethyl, hydroxyethyl (especially 2-hydroxyethyl), fluoroethyl (especially 2-fluoroethyl), difluoroethyl (especially 2,2-difluoroethyl), dimethoxyethyl
25 (especially 2,2-dimethoxyethyl), isopropyl, hydroxypropyl (especially 2-hydroxyprop-2-yl), dihydroxypropyl (especially 1,2-dihydroxyprop-2-yl), fluoropropyl (especially 2-fluoroprop-2-yl), cyanopropyl (especially 2-cyanoprop-2-yl), methoxycarbonylpropyl (especially 2-methoxycarbonylprop-2-yl), *tert*-butyl, hydroxybutyl (especially 1-hydroxy-
30 2-methylprop-2-yl), cyclopropyl, pyridinyl, furyl, thienyl, oxazolyl, methylthiazolyl, methyloxadiazolyl, imidazolylmethyl, triazolylmethyl,

trifluoromethyl, formyl, acetyl and methoxycarbonyl. Additional values of R^{11} include trifluoroethyl (especially 2,2,2-trifluoroethyl), methyl-triazolylmethyl (especially 2-methyl-2*H*-[1,2,4]triazol-3-ylmethyl) and pyridinylmethyl (especially pyridin-2-ylmethyl).

5 Specific values of R^{11} include methyl, ethyl, fluoroethyl (especially 2-fluoroethyl), difluoroethyl (especially 2,2-difluoroethyl), trifluoroethyl (especially 2,2,2-trifluoroethyl), isopropyl, methyl-triazolylmethyl (especially 2-methyl-2*H*-[1,2,4]triazol-3-ylmethyl) and pyridinylmethyl (especially pyridin-2-ylmethyl).

10 In a first embodiment, R^{11} represents methyl. In a second embodiment, R^{11} represents ethyl. In a third embodiment, R^{11} represents fluoroethyl (especially 2-fluoroethyl). In a fourth embodiment, R^{11} represents difluoroethyl (especially 2,2-difluoroethyl). In a fifth embodiment, R^{11} represents trifluoroethyl (especially 2,2,2-trifluoroethyl).
15 In a sixth embodiment, R^{11} represents isopropyl. In a seventh embodiment, R^{11} represents methyl-triazolylmethyl (especially 2-methyl-2*H*-[1,2,4]triazol-3-ylmethyl). In an eighth embodiment, R^{11} represents pyridinylmethyl (especially pyridin-2-ylmethyl). In a favoured embodiment, R^{11} represents 2-hydroxyprop-2-yl. In another embodiment,
20 R^{11} represents 2-fluoroprop-2-yl. In an additional embodiment, R^{11} represents trifluoromethyl.

 One representative subset of the compounds of formula IIA above is represented by the compounds of formula IIB, and pharmaceutically acceptable salts thereof:



(IIB)


wherein U, V, X¹¹, X¹² and R¹¹ are as defined above; and

R² represents hydrogen or fluoro.

5 In one embodiment, R² is hydrogen.

In another embodiment, R² is fluoro, in which case the fluorine atom R² is favourably attached to the phenyl ring at the 4-, 5- or 6-position (relative to the cyano group at position 2).

10 Another representative subset of the compounds of formula IIA above is represented by the compounds of formula IIC, and pharmaceutically acceptable salts thereof:



(IIC)

15 wherein U, V, X¹¹, X¹² and R¹¹ are as defined above; and

R³ represents hydrogen, fluoro, cyano or methyl.


In one embodiment, R³ is hydrogen.

In an additional embodiment, R³ is fluoro.

In another embodiment, R³ is cyano.

In a further embodiment, R³ is methyl.

5 A further representative subset of the compounds of formula IIA above is represented by the compounds of formula IID, and pharmaceutically acceptable salts thereof:



(IID)

10

wherein U, V, X¹¹, X¹², R³ and R¹¹ are as defined above; and

R⁴ represents hydrogen or fluoro.

Suitably, R⁴ represents hydrogen.

In another embodiment, R⁴ represents fluoro.

15 The present invention also provides a compound of formula IIB, IIC or IID as depicted above, or a pharmaceutically acceptable salt thereof, wherein

-U-V- represents -CH=CH-; and

X¹¹, X¹², R², R³, R⁴ and R¹¹ are as defined above.

20 Specific compounds within the scope of the present invention include:

2'-fluoro-5'-(7-methyl-8-oxo-7,8-dihydroimidazo[1,2-a]pyrazin-3-yl)-biphenyl-2-carbonitrile;

- 5'-(7-ethyl-8-oxo-7,8-dihydroimidazo[1,2- α]pyrazin-3-yl)-2'-fluorobiphenyl-2-carbonitrile;
- 2'-fluoro-5'-[7-(2-fluoroethyl)-8-oxo-7,8-dihydroimidazo[1,2- α]pyrazin-3-yl]biphenyl-2-carbonitrile;
- 5 5'-[7-(2,2-difluoroethyl)-8-oxo-7,8-dihydroimidazo[1,2- α]pyrazin-3-yl]-2'-fluorobiphenyl-2-carbonitrile;
- 4,2'-difluoro-5'-(7-methyl-8-oxo-7,8-dihydroimidazo[1,2- α]pyrazin-3-yl)-biphenyl-2-carbonitrile;
- 4,2'-difluoro-5'-(7-ethyl-8-oxo-7,8-dihydroimidazo[1,2- α]pyrazin-3-yl)-biphenyl-2-carbonitrile;
- 10 4,2'-difluoro-5'-[7-(2,2-difluoroethyl)-8-oxo-7,8-dihydroimidazo[1,2- α]pyrazin-3-yl]biphenyl-2-carbonitrile;
- 4,2'-difluoro-5'-[7-(1-methylethyl)-8-oxo-7,8-dihydroimidazo[1,2- α]pyrazin-3-yl]biphenyl-2-carbonitrile;
- 15 3-chloro-2'-fluoro-5'-(7-methyl-8-oxo-7,8-dihydroimidazo[1,2- α]pyrazin-3-yl)biphenyl-4-carbonitrile;
- 4,2'-difluoro-5'-[7-(2-fluoroethyl)-8-oxo-7,8-dihydroimidazo[1,2- α]pyrazin-3-yl]biphenyl-2-carbonitrile;
- 4'-fluoro-3'-(7-methyl-8-oxo-7,8-dihydroimidazo[1,2- α]pyrazin-3-yl)-biphenyl-2-carbonitrile;
- 20 5'-fluoro-3'-(7-methyl-8-oxo-7,8-dihydroimidazo[1,2- α]pyrazin-3-yl)-biphenyl-2-carbonitrile;
- 2,2'-difluoro-5'-(7-methyl-8-oxo-7,8-dihydroimidazo[1,2- α]pyrazin-3-yl)-biphenyl-4-carbonitrile;
- 25 4,2'-difluoro-5'-[7-(2,2,2-trifluoroethyl)-8-oxo-7,8-dihydroimidazo[1,2- α]pyrazin-3-yl]biphenyl-2-carbonitrile;
- 4,2'-difluoro-5'-[7-(2-methyl-2H-[1,2,4]triazol-3-ylmethyl)-8-oxo-7,8-dihydroimidazo[1,2- α]pyrazin-3-yl]biphenyl-2-carbonitrile;
- 3-[4-fluoro-3-(1-methyl-1H-[1,2,3]triazol-4-ylmethoxy)phenyl]-7-methyl-7H-imidazo[1,2- α]pyrazin-8-one;
- 30

- 3-[4-fluoro-3-(2-methyl-2*H*-[1,2,4]triazol-3-ylmethoxy)phenyl]-7-methyl-7*H*-imidazo[1,2-*a*]pyrazin-8-one;
- 7-ethyl-3-[4-fluoro-3-(2-methyl-2*H*-[1,2,4]triazol-3-ylmethoxy)phenyl]-7*H*-imidazo[1,2-*a*]pyrazin-8-one;
- 5 4,2'-difluoro-5'-[8-oxo-7-(pyridin-2-ylmethyl)-7,8-dihydroimidazo[1,2-*a*]pyrazin-3-yl)biphenyl-2-carbonitrile;
- 4,2'-difluoro-5'-(7-methyl-8-oxo-5,6,7,8-tetrahydroimidazo[1,2-*a*]pyrazin-3-yl)biphenyl-2-carbonitrile;
- 4,2'-difluoro-5'-(7-ethyl-8-oxo-5,6,7,8-tetrahydroimidazo[1,2-*a*]pyrazin-3-yl)biphenyl-2-carbonitrile;
- 10 5,2'-difluoro-5'-(7-ethyl-8-oxo-5,6,7,8-tetrahydroimidazo[1,2-*a*]pyrazin-3-yl)biphenyl-2-carbonitrile;
- 6,2'-difluoro-5'-(7-ethyl-8-oxo-5,6,7,8-tetrahydroimidazo[1,2-*a*]pyrazin-3-yl)biphenyl-2-carbonitrile;
- 15 6,2'-difluoro-5'-(7-methyl-8-oxo-7,8-dihydroimidazo[1,2-*a*]pyrazin-3-yl)-biphenyl-2-carbonitrile;
- 6,2'-difluoro-5'-(7-ethyl-8-oxo-7,8-dihydroimidazo[1,2-*a*]pyrazin-3-yl)-biphenyl-2-carbonitrile;
- 5,2'-difluoro-5'-(7-methyl-8-oxo-5,6,7,8-tetrahydroimidazo[1,2-*a*]pyrazin-3-yl)biphenyl-2-carbonitrile;
- 20 4,2'-difluoro-5'-[8-oxo-7-(pyridin-2-ylmethyl)-5,6,7,8-tetrahydroimidazo[1,2-*a*]pyrazin-3-yl)biphenyl-2-carbonitrile;
- 6,2'-difluoro-5'-(7-methyl-8-oxo-5,6,7,8-tetrahydroimidazo[1,2-*a*]pyrazin-3-yl)biphenyl-2-carbonitrile;
- 25 and pharmaceutically acceptable salts thereof.

Also provided by the present invention is a method for the treatment and/or prevention of anxiety which comprises administering to a patient in need of such treatment an effective amount of a compound of formula I as defined above or a pharmaceutically acceptable salt thereof.

- 30 Further provided by the present invention is a method for the treatment and/or prevention of convulsions (e.g. in a patient suffering from

epilepsy or a related disorder) which comprises administering to a patient in need of such treatment an effective amount of a compound of formula I as defined above or a pharmaceutically acceptable salt thereof.

5 The binding affinity (K_i) of the compounds according to the present invention for the $\alpha 3$ subunit of the human GABA_A receptor is conveniently as measured in the assay described hereinbelow. The $\alpha 3$ subunit binding affinity (K_i) of the anxiolytic compounds of the invention is ideally 50 nM or less, preferably 10 nM or less, and more preferably 5 nM or less.

10 The anxiolytic compounds according to the present invention will ideally elicit at least a 40%, preferably at least a 50%, and more preferably at least a 60%, potentiation of the GABA EC₂₀ response in stably transfected recombinant cell lines expressing the $\alpha 3$ subunit of the human GABA_A receptor. Moreover, the compounds of the invention will ideally elicit at most a 30%, preferably at most a 20%, and more preferably at
15 most a 10%, potentiation of the GABA EC₂₀ response in stably transfected recombinant cell lines expressing the $\alpha 1$ subunit of the human GABA_A receptor.

The potentiation of the GABA EC₂₀ response in stably transfected cell lines expressing the $\alpha 3$ and $\alpha 1$ subunits of the human GABA_A receptor
20 can conveniently be measured by procedures analogous to the protocol described in Wafford *et al.*, *Mol. Pharmacol.*, 1996, 50, 670-678. The procedure will suitably be carried out utilising cultures of stably transfected eukaryotic cells, typically of stably transfected mouse Ltk-fibroblast cells.

25 The compounds according to the present invention may exhibit anxiolytic activity, as may be demonstrated by a positive response in the elevated plus maze and conditioned suppression of drinking tests (cf. Dawson *et al.*, *Psychopharmacology*, 1995, 121, 109-117). Moreover, the compounds of the invention are likely to be substantially non-sedating, as
30 may be confirmed by an appropriate result obtained from the response

sensitivity (chain-pulling) test (cf. Bayley *et al.*, *J. Psychopharmacol.*, 1996, 10, 206-213).

5 The compounds according to the present invention may also exhibit anticonvulsant activity. This can be demonstrated by the ability to block pentylenetetrazole-induced seizures in rats and mice, following a protocol analogous to that described by Bristow *et al.* in *J. Pharmacol. Exp. Ther.*, 1996, 279, 492-501.

10 In another aspect, the present invention provides a method for the treatment and/or prevention of cognitive disorders, including dementing conditions such as Alzheimer's disease, which comprises administering to a patient in need of such treatment an effective amount of a compound of formula I as defined above or a pharmaceutically acceptable salt thereof.

15 Cognition enhancement can be shown by testing the compounds in the Morris watermaze as reported by McNamara and Skelton, *Psychobiology*, 1993, 21, 101-108. Further details of relevant methodology are described in WO 96/25948.

20 Cognitive disorders for which the compounds of the present invention may be of benefit include delirium, dementia, amnesic disorders, and cognition deficits, including age-related memory deficits, due to traumatic injury, stroke, Parkinson's disease and Down Syndrome. Any of these conditions may be attributable to substance abuse or withdrawal. Examples of dementia include dementia of the Alzheimer's type with early or late onset, and vascular dementia, any of which may be uncomplicated or accompanied by delirium, delusions or depressed mood;
25 and dementia due to HIV disease, head trauma, Parkinson's disease or Creutzfeld-Jakob disease.

30 In order to elicit their behavioural effects, the compounds of the invention will ideally be brain-penetrant; in other words, these compounds will be capable of crossing the so-called "blood-brain barrier". Preferably, the compounds of the invention will be capable of exerting their beneficial therapeutic action following administration by the oral route.


The invention also provides pharmaceutical compositions comprising one or more compounds of this invention in association with a pharmaceutically acceptable carrier. Preferably these compositions are in unit dosage forms such as tablets, pills, capsules, powders, granules, sterile parenteral solutions or suspensions, metered aerosol or liquid sprays, drops, ampoules, auto-injector devices or suppositories; for oral, parenteral, intranasal, sublingual or rectal administration, or for administration by inhalation or insufflation. For preparing solid compositions such as tablets, the principal active ingredient is mixed with a pharmaceutical carrier, e.g. conventional tableting ingredients such as corn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate, dicalcium phosphate or gums, and other pharmaceutical diluents, e.g. water, to form a solid preformulation composition containing a homogeneous mixture of a compound of the present invention, or a pharmaceutically acceptable salt thereof. When referring to these preformulation compositions as homogeneous, it is meant that the active ingredient is dispersed evenly throughout the composition so that the composition may be readily subdivided into equally effective unit dosage forms such as tablets, pills and capsules. This solid preformulation composition is then subdivided into unit dosage forms of the type described above containing from 0.1 to about 500 mg of the active ingredient of the present invention. Typical unit dosage forms contain from 1 to 100 mg, for example 1, 2, 5, 10, 25, 50 or 100 mg, of the active ingredient. The tablets or pills of the novel composition can be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action. For example, the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former. The two components can be separated by an enteric layer which serves to resist disintegration in the stomach and permits the inner component to pass intact into the duodenum or to be delayed in release. A variety of materials can be used for such enteric layers or coatings, such

materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol and cellulose acetate.

The liquid forms in which the novel compositions of the present invention may be incorporated for administration orally or by injection include aqueous solutions, suitably flavoured syrups, aqueous or oil suspensions, and flavoured emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil or peanut oil, as well as elixirs and similar pharmaceutical vehicles. Suitable dispersing or suspending agents for aqueous suspensions include synthetic and natural gums such as tragacanth, acacia, alginate, dextran, sodium carboxymethylcellulose, methylcellulose, polyvinyl-pyrrolidone or gelatin.

In the treatment of neurological disorders, a suitable dosage level is about 0.01 to 250 mg/kg per day, preferably about 0.05 to 100 mg/kg per day, and especially about 0.05 to 5 mg/kg per day. The compounds may be administered on a regimen of 1 to 4 times per day.

The compounds in accordance with the present invention may be prepared by a process which comprises attachment of the R^1 moiety to a compound of formula III:



wherein U, V, X^1 , X^2 , Y and Z are as defined above; by conventional alkylation or acylation methods.

For instance, where R^1 in the compounds of formula I above represents an optionally substituted C_{1-6} alkyl group, the moiety R^1 may


be attached by treating the appropriate compound of formula III with a suitable alkyl halide, e.g. iodomethane, iodoethane, 1-bromo-2-fluoroethane, 2-bromo-1,1-difluoroethane, 1-iodo-2,2,2-trifluoroethane or 2-bromopropane, typically in the presence of a base such as sodium hydride.

5 Similarly, where R^1 represents an optionally substituted heteroaryl(C_{1-6})alkyl group, the moiety R^1 may be attached by reacting the appropriate compound of formula III with a suitable alkylating agent, e.g. 3-chloromethyl-2-methyl-2*H*-[1,2,4]triazole or 2-chloromethylpyridine, typically in the presence of a base such as sodium hydride. Alternatively,
10 where R^1 in the compounds of formula I above represents methyl, the methyl group R^1 may be attached by treating the appropriate compound of formula III with a strong base such as hexamethyldisilazane, followed by chloro(chloromethyl)dimethylsilane; and subsequently treating the compound thereby obtained with cesium fluoride.

15 Except where X^1 and X^2 both simultaneously represent hydrogen, the compounds of formula III above are novel compounds and represent a further feature of the present invention.


The compounds of formula III may suitably be prepared from the appropriate methoxy-substituted compound of formula IV:

20




wherein U, V, X^1 , X^2 , Y and Z are as defined above; by treatment with hydrogen bromide, typically in acetic acid.

In another procedure, the compounds in accordance with the present invention may be prepared by a process which comprises reacting a compound of formula V with a compound of formula VI:



(V)




(VI)

wherein U, V, X¹, X², Y, Z and R¹ are as defined above, L¹ represents a suitable leaving group, and M¹ represents a boronic acid moiety -B(OH)₂ or a cyclic ester thereof formed with an organic diol, e.g. pinacol, 1,3-propanediol or neopentyl glycol, or M¹ represents -Sn(Alk)₃ in which Alk represents a C₁-₆ alkyl group, typically *n*-butyl; in the presence of a transition metal catalyst.

The leaving group L¹ is typically a halogen atom, e.g. bromo.

The transition metal catalyst of use in the reaction between compounds V and VI is suitably palladium(II) acetate, in which case the reaction is typically accomplished in the presence of triphenylphosphine. The reaction is conveniently carried out at an elevated temperature in a solvent such as 1,4-dioxane, typically in the presence of sodium carbonate.


The intermediates of formula V may be prepared by attaching the R¹ moiety to a compound of formula VII:



(VII)

wherein U, V and L¹ are as defined above; under conditions analogous to those described above for attachment of the R¹ moiety to a compound of formula III.

- 5 The intermediates of formula VII may be prepared from the appropriate methoxy-substituted precursor of formula VIII:




(VIII)


- 10 wherein U, V and L¹ are as defined above; by treatment with hydrogen bromide, typically in acetic acid.

In a further procedure, the compounds in accordance with the present invention may be prepared by a process which comprises reacting a compound of formula IX with a compound of formula X:

15



(IX)



(X)

wherein U, V, X¹, X², Y, Z, R¹ and L¹ are as defined above; in the presence of a transition metal catalyst.

- 20 The transition metal catalyst of use in the reaction between compounds IX and X is suitably palladium(II) acetate, in which case the reaction is typically accomplished in the presence of triphenylphosphine.

The reaction is conveniently carried out at an elevated temperature in a solvent such as *N,N*-dimethylacetamide, typically in the presence of potassium acetate.

5 The intermediates of formula III, IV, V, VII, VIII and IX wherein -U-V- represents -CH₂-CH₂- may be prepared from the corresponding compound wherein -U-V- represents -CH=CH- by catalytic hydrogenation.

The compounds of formula IV, VI, VIII, IX and X may conveniently be prepared by the procedures described in WO 02/10170, or by methods analogous thereto.

10 It will be understood that any compound of formula I initially obtained from any of the above processes may, where appropriate, subsequently be elaborated into a further compound of formula I by techniques known from the art. For example, a compound of formula I wherein R¹ represents -C(O-Alk¹)₂R^a initially obtained, wherein Alk¹ is
15 C₁₋₆ alkyl, typically methyl or ethyl, may be converted into the corresponding compound of formula I wherein R¹ represents -COR^a by hydrolysis with a mineral acid, typically aqueous hydrochloric acid. A compound wherein R¹ represents formyl may be reduced with sodium triacetoxyborohydride to the corresponding compound wherein R¹
20 represents hydroxymethyl. A compound of formula I wherein R¹ represents C₂₋₆ alkoxy carbonyl may be reduced with lithium aluminium hydride to the corresponding compound of formula I wherein R¹ represents hydroxymethyl. A compound of formula I wherein R¹ represents hydroxymethyl may be oxidised to the corresponding compound of formula
25 I wherein R¹ represents formyl by treatment with manganese dioxide. Alternatively, the compound of formula I wherein R¹ represents formyl may be reacted with a Grignard reagent of formula R^aMgBr to afford a compound of formula I wherein R¹ represents -CH(OH)R^a, and this compound may in turn be oxidised using manganese dioxide to the
30 corresponding compound of formula I wherein R¹ represents -COR^a. A compound of formula I wherein R¹ represents -CH(OH)R^a may be

converted into the corresponding compound of formula I wherein R¹ represents -CHFR^a by treatment with (diethylamino)sulfur trifluoride (DAST). Similarly, a compound of formula I wherein R¹ represents -COR^a may be converted into the corresponding compound of formula I wherein R¹ represents -CF₂R^a by treatment with DAST. A compound of formula I wherein R¹ represents -COCH₃ may be treated with thioacetamide in the presence of pyridinium tribromide to furnish the corresponding compound of formula I wherein R¹ represents 2-methylthiazol-5-yl. Moreover, a compound of formula I wherein R¹ is formyl may be treated with (p-tolylsulfonyl)methyl isocyanide (TosMIC) in the presence of potassium carbonate to afford the corresponding compound of formula I wherein R¹ represents oxazol-5-yl. A compound of formula I wherein R¹ represents hydroxymethyl may be treated with carbon tetrabromide and triphenylphosphine to afford the corresponding compound of formula I wherein R¹ represents bromomethyl, which may then be reacted (typically *in situ*) with the sodium salt of imidazole or 1*H*-[1,2,4]triazole to provide a compound of formula I wherein R¹ represents imidazol-1-ylmethyl or [1,2,4]triazol-1-ylmethyl respectively; or with the sodium salt of 1*H*-[1,2,3]triazole to provide a mixture of compounds of formula I wherein R¹ represents [1,2,3]triazol-1-ylmethyl and [1,2,3]triazol-2-ylmethyl; or with morpholine to provide a compound of formula I wherein R¹ represents morpholin-4-ylmethyl. A compound of formula I wherein Z is substituted with methoxy may be converted to the corresponding compound wherein Z is substituted with hydroxy by treatment with boron tribromide. A compound of formula I wherein -U-V- represents -CH=CH- may be converted into the corresponding compound wherein -U-V- represents -CH₂-CH₂- by catalytic hydrogenation.

Where a mixture of products is obtained from any of the processes described above for the preparation of compounds according to the invention, the desired product can be separated therefrom at an appropriate stage by conventional methods such as preparative HPLC; or

column chromatography utilising, for example, silica and/or alumina in conjunction with an appropriate solvent system.

Where the above-described processes for the preparation of the compounds according to the invention give rise to mixtures of stereoisomers, these isomers may be separated by conventional techniques such as preparative chromatography. The novel compounds may be prepared in racemic form, or individual enantiomers may be prepared either by enantiospecific synthesis or by resolution. The novel compounds may, for example, be resolved into their component enantiomers by standard techniques such as preparative HPLC, or the formation of diastereomeric pairs by salt formation with an optically active acid, such as (-)-di-*p*-toluoyl-d-tartaric acid and/or (+)-di-*p*-toluoyl-l-tartaric acid, followed by fractional crystallization and regeneration of the free base. The novel compounds may also be resolved by formation of diastereomeric esters or amides, followed by chromatographic separation and removal of the chiral auxiliary.

During any of the above synthetic sequences it may be necessary and/or desirable to protect sensitive or reactive groups on any of the molecules concerned. This may be achieved by means of conventional protecting groups, such as those described in *Protective Groups in Organic Chemistry*, ed. J.F.W. McOmie, Plenum Press, 1973; and T.W. Greene & P.G.M. Wuts, *Protective Groups in Organic Synthesis*, John Wiley & Sons, 3rd edition, 1999. The protecting groups may be removed at a convenient subsequent stage using methods known from the art.

The following Examples illustrate the preparation of compounds according to the invention.

The compounds in accordance with this invention potently inhibit the binding of [³H]-flumazenil to the benzodiazepine binding site of human GABA_A receptors containing the α 2 and/or α 3 and/or α 5 subunit stably expressed in Ltk⁻ cells.

Reagents

- Phosphate buffered saline (PBS).
- Assay buffer: 10 mM KH_2PO_4 , 100 mM KCl, pH 7.4 at room temperature.
- [^3H]-Flumazenil (18 nM for $\alpha 1\beta 3\gamma 2$ cells; 18 nM for $\alpha 2\beta 3\gamma 2$ cells; 10 nM for $\alpha 3\beta 3\gamma 2$ cells; 10 nM for $\alpha 5\beta 3\gamma 2$ cells) in assay buffer.
- Flunitrazepam 100 μM in assay buffer.
- Cells resuspended in assay buffer (1 tray to 10 ml).

Harvesting Cells

- Supernatant is removed from cells. PBS (approximately 20 ml) is added. The cells are scraped and placed in a 50 ml centrifuge tube. The procedure is repeated with a further 10 ml of PBS to ensure that most of the cells are removed. The cells are pelleted by centrifuging for 20 min at 3000 rpm in a benchtop centrifuge, and then frozen if desired. The pellets are resuspended in 10 ml of buffer per tray (25 cm x 25 cm) of cells.

Assay

Can be carried out in deep 96-well plates or in tubes. Each tube contains:

- 300 μl of assay buffer.
- 50 μl of [^3H]-flumazenil (final concentration for $\alpha 1\beta 3\gamma 2$: 1.8 nM; for $\alpha 2\beta 3\gamma 2$: 1.8 nM; for $\alpha 3\beta 3\gamma 2$: 1.0 nM; for $\alpha 5\beta 3\gamma 2$: 1.0 nM).
- 50 μl of buffer or solvent carrier (e.g. 10% DMSO) if compounds are dissolved in 10% DMSO (total); test compound or flunitrazepam (to determine non-specific binding), 10 μM final concentration.
- 100 μl of cells.

- Assays are incubated for 1 hour at 40°C, then filtered using either a Tomtec or Brandel cell harvester onto GF/B filters followed by 3 x 3 ml washes with ice cold assay buffer. Filters are dried and counted by liquid scintillation counting. Expected values for total binding are 3000-4000 dpm for total counts and less than 200 dpm for non-specific binding if

using liquid scintillation counting, or 1500-2000 dpm for total counts and less than 200 dpm for non-specific binding if counting with meltilex solid scintillant. Binding parameters are determined by non-linear least squares regression analysis, from which the inhibition constant K_i can be calculated for each test compound.

The compounds of the accompanying Examples were tested in the above assay, and all were found to possess a K_i value for displacement of [^3H]-flumazenil from the $\alpha 2$ and/or $\alpha 3$ and/or $\alpha 5$ subunit of the human GABA_A receptor of 100 nM or less.

EXAMPLE 1

2'-Fluoro-5'-(7-methyl-8-oxo-7,8-dihydroimidazo[1,2- α]pyrazin-3-yl)-biphenyl-2-carbonitrile

A suspension of 2,3-dichloropyrazine (35 g, 0.23 mol) in 25% aqueous ammonia (200 ml) was heated at 100°C for 12 h in a PTFE-lined pressure reactor (terminal pressure 100 psi). The reaction was cooled to ambient temperature and the resulting crystalline solid collected by filtration. This solid was triturated with water (150 ml) and dried to afford 2-amino-3-chloropyrazine as a buff-coloured crystalline solid (28 g, 92%): δ_{H} (400 MHz, DMSO) 6.78 (2H, br s), 7.56 (1H, d, J 2.5), 7.95 (1H, d, J 2.5).

Bromoacetaldehyde diethyl acetal (45 ml, 0.29 mol) was treated with water (33 ml) and 48% hydrobromic acid (33 ml) and this mixture was heated at 95°C for 90 min. The reaction was cooled, diluted with propan-2-ol (300 ml) and treated with sodium hydrogencarbonate (33 g) added in portions. This mixture was stirred for 30 min then filtered. The filtrate was treated with 2-amino-3-chloropyrazine (25 g, 0.19 mol) and then heated at 90°C for 16 h. The reaction was cooled to ambient temperature, concentrated to about one-third volume and then treated with 48% hydrobromic acid (25 ml). More propan-2-ol (300 ml) was added

and the mixture aged for 1 h. The resulting solid was collected by filtration, washed with propan-2-ol and then dissolved in water (500 ml). This solution was made basic by adding solid sodium hydrogencarbonate and then extracted with chloroform (3 x 250 ml). The organics were
5 combined, dried over anhydrous magnesium sulphate, filtered and concentrated to give a solid. Trituration with diethyl ether afforded 8-chloroimidazo[1,2-*a*]pyrazine as an off-white solid (18.6 g, 63%): δ_H (360 MHz, DMSO) 7.73 (1H, d, *J* 4.5), 7.87 (1H, d, *J* 1), 8.28 (1H, d, *J* 1), 8.67 (1H, d, *J* 4.5).

10 A cooled (0°C) suspension of 8-chloroimidazo[1,2-*a*]pyrazine (18.6 g, 0.12 mol) and sodium acetate (29.8 g, 0.36 mol) in methanol (125 ml, pre-saturated with solid potassium bromide) was treated with bromine (6.5 ml, 0.13 mol) added dropwise over 5 min. After stirring for 10 min thin-layer chromatography indicated no starting material. Solid sodium
15 sulphite (15.3 g, 0.12 mol) was then added to the slurry and stirring continued for 10 min. The mixture was then treated with saturated aqueous sodium hydrogencarbonate (650 ml) added in portions. This mixture was extracted with dichloromethane (2 x 350 ml). The organics were combined, dried over anhydrous magnesium sulphate, filtered and
20 concentrated to afford 3-bromo-8-chloroimidazo[1,2-*a*]pyrazine as a cream-coloured solid: δ_H (400 MHz, CDCl₃) 7.82 (1H, d, *J* 4.5), 7.83 (1H, s), 8.05 (1H, d, *J* 4.5). This solid was suspended in 1:1 dichloromethane/methanol (150 ml) and treated with solid sodium methoxide (9.8 g, 0.18 mol). The resulting mixture was then stirred at 40°C for 2 h. The reaction was
25 cooled, diluted with water (750 ml) then extracted with dichloromethane (600 ml). The organics were dried over anhydrous magnesium sulphate, filtered and concentrated to give 3-bromo-8-methoxyimidazo[1,2-*a*]pyrazine as a white solid (24.5 g, 89% over 2 steps): δ_H (360 MHz, DMSO) 4.06 (3H, s), 7.57 (1H, d, *J* 4.5), 7.81 (1H, s), 8.03 (1H, d, *J* 4.5).

30 A mixture of 3-bromo-8-methoxyimidazo[1,2-*a*]pyrazine (680 mg, 3 mmol) and 2'-fluoro-5'-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-

biphenyl-2-carbonitrile (prepared as described in WO 02/074773) (1.45 g, 4.5 mmol) in tetrahydrofuran (9 ml) was treated with 2M sodium carbonate (3 ml) then degassed with nitrogen for 10 min.

Tetrakis(triphenylphosphine)palladium(0) (100 mg, 0.09 mmol) was added and this mixture was heated under reflux for 12 h. The reaction was cooled and the majority of the solvent removed on a rotary evaporator.

The residue was partitioned between dichloromethane and water. The organics were washed with water, brine, dried over anhydrous magnesium sulphate, filtered and concentrated *in vacuo*. Purification of the residue by

chromatography on silica gel eluting with 2% methanol in dichloromethane gave 2'-fluoro-5'-(8-methoxyimidazo[1,2-*a*]pyrazin-3-yl)-biphenyl-2-carbonitrile as a cream solid (768 mg, 74%): δ_H (400 MHz, $CDCl_3$) 4.19 (3H, s), 7.38-7.46 (2H, m), 7.53-7.64 (4H, m), 7.71 (1H, td, *J* 8 and 1.5), 7.73 (1H, s), 7.85 (1H, dd, *J* 8 and 1), 8.02 (1H, d, *J* 4.5); *m/z* (ES⁺) 345 [M+H]⁺.

A suspension of 2'-fluoro-5'-(8-methoxyimidazo[1,2-*a*]pyrazin-3-yl)-biphenyl-2-carbonitrile (750 mg, 2.2 mmol) in hydrogen bromide (30 wt % in acetic acid, 10 ml) was heated at 95°C for 45 min. The reaction was cooled, poured into ice water and neutralised by the addition of solid sodium hydrogencarbonate. The resulting solid was collected by filtration and air-dried, then triturated with ether, to afford 2'-fluoro-5'-(8-oxo-7,8-dihydroimidazo[1,2-*a*]pyrazin-3-yl)biphenyl-2-carbonitrile as a cream-coloured solid (550 mg, 76%): δ_H (360 MHz, DMSO) 6.92 (1H, t, *J* 6), 7.49 (1H, d, *J* 5), 7.60-7.71 (2H, m), 7.75-7.89 (5H, m), 8.03 (1H, dd, *J* 7 and 0.5), 11.38 (1H, d, *J* 5.5); *m/z* (ES⁺) 331 [M+H]⁺.

A suspension of 2'-fluoro-5'-(8-oxo-7,8-dihydroimidazo[1,2-*a*]pyrazin-3-yl)biphenyl-2-carbonitrile (250 mg, 0.75 mmol) in acetonitrile (10 ml) was treated with 1,1,1,3,3,3-hexamethyldisilazane (90 μ l, 0.41 mmol) and then heated at reflux for 2 h. The resulting gel-like mixture was diluted with acetonitrile (5 ml) then treated with chloro(chloromethyl)-dimethylsilane (110 μ l, 0.83 mmol) and heating at reflux continued for 24

h. The reaction was cooled, the acetonitrile removed *in vacuo* and the residue treated with 1,2-dimethoxyethane (12 ml). Caesium fluoride (160 mg, 1.4 mmol) was then added and the reaction heated at reflux for 6 h. After cooling to ambient temperature the mixture was dissolved in 1:1 dichloromethane/methanol and pre-adsorbed onto silica. Purification by chromatography on silica eluting with 4% methanol in dichloromethane (containing 0.5% ammonia) followed by 8% methanol in dichloromethane (containing 0.5% ammonia) gave 2'-fluoro-5'-(7-methyl-8-oxo-7,8-dihydroimidazo[1,2-*a*]pyrazin-3-yl)biphenyl-2-carbonitrile as a cream-coloured solid (65 mg, 25%): δ_{H} (400 MHz, DMSO) 3.47 (3H, s), 7.19 (1H, d, *J* 6), 7.57-7.88 (8H, m), 8.04 (1H, dd, *J* 8 and 1); *m/z* (ES⁺) 345 [M+H]⁺.

EXAMPLE 2

15 5'-(7-Ethyl-8-oxo-7,8-dihydroimidazo[1,2-*a*]pyrazin-3-yl)-2'-fluorobiphenyl-2-carbonitrile

A suspension of 2'-fluoro-5'-(8-oxo-7,8-dihydroimidazo[1,2-*a*]pyrazin-3-yl)biphenyl-2-carbonitrile (50.0 mg, 0.51 mmol) in 1,2-dimethoxyethane (2 ml) and *N,N*-dimethylformamide (0.5 ml) was treated with sodium hydride (6.4 mg of a 60% dispersion in mineral oil, 0.16 mmol). After stirring at ambient temperature for 10 min, lithium bromide (26.3 mg, 0.30 mmol) was added, and stirring continued for 15 min. Iodoethane (24.2 μ l, 0.30 mmol) was added and the solution heated at 65°C for 18 h. Water (15 ml) was added and the resulting mixture was extracted with dichloromethane (3 x 10 ml). The combined organic layers were washed with water (10 ml), saturated sodium chloride solution (10 ml), dried over anhydrous magnesium sulphate then concentrated *in vacuo*. The crude product was purified by flash chromatography on silica gel, eluting with 2% methanol in dichloromethane. Crystallisation from methanol afforded 5'-(7-ethyl-8-oxo-7,8-dihydroimidazo[1,2-*a*]pyrazin-3-yl)-2'-fluorobiphenyl-2-carbonitrile as a white solid (23.9 mg, 44%): δ_{H} (500 MHz, CDCl₃) 1.38

(3H, t, *J* 7.2), 4.06 (2H, q, *J* 7.2), 6.72 (1H, d, *J* 5.9), 7.39 (1H, t, *J* 9.3), 7.44 (1H, d, *J* 5.9), 7.53-7.61 (5H, m), 7.69-7.73 (1H, m), 7.84 (1H, d, *J* 7.3); *m/z* (ES⁺) 359 [M+H]⁺.

5

EXAMPLE 32'-Fluoro-5'-[7-(2-fluoroethyl)-8-oxo-7,8-dihydroimidazo[1,2-*a*]pyrazin-3-yl]biphenyl-2-carbonitrile

The title compound was prepared in the same way as described in Example 2, using 1-bromo-2-fluoroethane instead of iodoethane: δ_{H} (500 MHz, CDCl₃) 4.27 (1H, t, *J* 4.5), 4.32 (1H, t, *J* 4.5), 4.71 (1H, t, *J* 4.4), 4.81 (1H, t, *J* 4.5), 6.80 (1H, d, *J* 5.9), 7.40-7.43 (2H, m), 7.53-7.61 (4H, m), 7.63 (1H, s), 7.69-7.73 (1H, m), 7.85 (1H, d, *J* 7.7); *m/z* (ES⁺) 377 [M+H]⁺.

15

EXAMPLE 45'-[7-(2,2-Difluoroethyl)-8-oxo-7,8-dihydroimidazo[1,2-*a*]pyrazin-3-yl]-2'-fluorobiphenyl-2-carbonitrile

The title compound was prepared using the method described in Example 2, using 2-bromo-1,1-difluoroethane instead of iodoethane: δ_{H} (500 MHz, CDCl₃) 4.31 (2H, td, *J* 13 and 4.4), 6.14 (1H, tt, *J* 56 and 4.4), 6.74 (1H, d, *J* 6.1), 7.41 (1H, t, *J* 9.3), 7.46 (1H, d, *J* 6.1), 7.55-7.60 (4H, m), 7.65 (1H, s), 7.70-7.73 (1H, m), 7.85 (1H, d, *J* 7.1); *m/z* (ES⁺) 395 [M+H]⁺.

25

EXAMPLE 54,2'-Difluoro-5'-(7-methyl-8-oxo-7,8-dihydroimidazo[1,2-*a*]pyrazin-3-yl)-biphenyl-2-carbonitrile

A suspension of 3-bromo-8-methoxyimidazo[1,2-*a*]pyrazine (1.6 g, 7 mmol) in hydrogen bromide (30 wt % in acetic acid, 15 ml) was heated at 80°C for 90 min. The reaction was cooled, diluted with water (75 ml) then

neutralised with solid sodium hydrogencarbonate. The resulting solid was collected by filtration, washed with water then dried under vacuum to afford 3-bromo-7*H*-imidazo[1,2-*a*]pyrazin-8-one as a white powder: δ_{H} (360 MHz, DMSO) 6.99 (1H, d, *J* 5.6), 7.29 (1H, d, *J* 5.6), 7.62 (1H, s). This powder was suspended in *N,N*-dimethylformamide (15 ml) then treated with sodium hydride (203 mg of a 60% dispersion in mineral oil, 8.4 mmol). The resulting mixture was heated at 60°C for 20 min then treated with iodomethane (870 μ l, 14 mmol). After stirring for 15 min the reaction was cooled, diluted cautiously with water (150 ml) and then extracted with dichloromethane (2 x 100 ml). The organics were combined, washed with water, dried over anhydrous magnesium sulphate, filtered and concentrated under high vacuum. The residue was triturated with diethyl ether and the resulting solid collected by filtration to furnish 3-bromo-7-methyl-7*H*-imidazo[1,2-*a*]pyrazin-8-one as a white solid (1.4 g, 88% over 2 steps): δ_{H} (360 MHz, DMSO) 3.45 (3H, s), 7.28 (1H, d, *J* 6), 7.39 (1H, d, *J* 5.6), 7.62 (1H, s).

A mixture of 3-bromo-7-methyl-7*H*-imidazo[1,2-*a*]pyrazin-8-one (171 mg, 0.75 mmol), 4,2'-difluoro-5'-(5,5-dimethyl-[1,3,2]dioxaborinan-2-yl)biphenyl-2-carbonitrile (prepared as described in WO 02/074773) (392 mg, 1.2 mmol), palladium(II) acetate (7 mg, 0.03 mmol) and triphenylphosphine (8 mg, 0.03 mmol) in 1,4-dioxane (3 ml) and 2M aqueous sodium carbonate (0.75 ml) was heated at 80°C for 3 h. The reaction was cooled then diluted with ethyl acetate (25 ml). The mixture was extracted with 4N hydrochloric acid (25 ml) and the organics discarded. The aqueous was washed with ethyl acetate, filtered through GF/A glass microfibre filter paper and the filtrate made basic with solid sodium hydrogencarbonate. The resulting solid was collected by filtration, triturated with water and dried under high vacuum to afford 4,2'-difluoro-5'-(7-methyl-8-oxo-7,8-dihydroimidazo[1,2-*a*]pyrazin-3-yl)biphenyl-2-carbonitrile as a cream-coloured solid (175 mg, 64%): δ_{H} (500 MHz, DMSO)

3.47 (3H, s), 7.19 (1H, d, J 6.0), 7.57-7.61 (2H, m), 7.72 (1H, s), 7.76-7.86 (4H, m), 8.08 (1H, dd, J 9 and 3); m/z (ES⁺) 363 [M+H]⁺.

EXAMPLE 6

5

4,2'-Difluoro-5'-(7-ethyl-8-oxo-7,8-dihydroimidazo[1,2- α]pyrazin-3-yl)-biphenyl-2-carbonitrile

3-Bromo-7*H*-imidazo[1,2- α]pyrazin-8-one (prepared as described in Example 5, 1.5 g, 7 mmol) was suspended in *N,N*-dimethylformamide (15 ml) then treated with sodium hydride (420 mg of a 60% dispersion in mineral oil, 10.5 mmol). The resulting mixture was heated at 60°C for 20 min then treated with iodoethane (840 μ l, 10.5 mmol). After stirring for 40 min the reaction was cooled, diluted cautiously with water (150 ml) and then extracted with dichloromethane (2 x 100 ml). The organics were combined, washed with water, dried over anhydrous magnesium sulphate, filtered and concentrated under high vacuum. The residue was triturated with diethyl ether and the resulting solid collected by filtration and recrystallized from ethyl acetate/methanol to furnish 3-bromo-7-ethyl-7*H*-imidazo[1,2- α]pyrazin-8-one as a white solid (0.34 g): δ_H (400 MHz, DMSO) 1.23 (3H, t, J 7), 3.94 (2H, q, J 7), 7.31 (1H, d, J 6), 7.41 (1H, d, J 6), 7.62 (1H, s); m/z (ES⁺) 244 and 242 [M+H]⁺.

Reaction of 3-bromo-7-ethyl-7*H*-imidazo[1,2- α]pyrazin-8-one with 4,2'-difluoro-5'-(5,5-dimethyl-[1,3,2]dioxaborinan-2-yl)biphenyl-2-carbonitrile under the same Suzuki coupling conditions as described in Example 5 gave 4,2'-difluoro-5'-(7-ethyl-8-oxo-7,8-dihydroimidazo[1,2- α]pyrazin-3-yl)biphenyl-2-carbonitrile after recrystallization from ethyl acetate/dichloromethane: δ_H (400 MHz, DMSO) 1.25 (3H, t, J 7.1), 3.96 (2H, q, J 7.1), 7.22 (1H, d, J 6.0), 7.57-7.61 (2H, m), 7.72 (1H, s), 7.76-7.84 (4H, m), 8.07 (1H, dd, J 8.6 and 2.7); m/z (ES⁺) 377 [M+H]⁺; Found C, 66.87; H, 3.54; N, 14.62. C₂₁H₁₄F₂N₄O requires C, 67.02; H, 3.75; N, 14.89%.

EXAMPLE 7

5 4,2'-Difluoro-5'-[7-(2,2-difluoroethyl)-8-oxo-7,8-dihydroimidazo[1,2-
α]pyrazin-3-yl]biphenyl-2-carbonitrile

The title compound was prepared using the method described in Example 6, using 2-bromo-1,1-difluoroethane instead of iodoethane: δ_H (400 MHz, DMSO) 4.44 (2H, td, J 13 and 4.4), 6.36 (1H, tt, J 56 and 4.4), 7.19 (1H, d, J 6.1), 7.60-7.65 (2H, m), 7.74-7.86 (5H, m), 8.08 (1H, dd, J 8.6 and 2.7); m/z (ES⁺) 413 [M+H]⁺; Found C, 60.88; H, 2.97; N, 13.38. C₂₁H₁₂F₄N₄O requires C, 61.17; H, 2.93; N, 13.59%.

EXAMPLE 8

15 4,2'-Difluoro-5'-[7-(1-methylethyl)-8-oxo-7,8-dihydroimidazo[1,2-α]pyrazin-
3-yl]biphenyl-2-carbonitrile

The title compound was prepared using the method described in Example 6, using 2-bromopropane instead of iodoethane: δ_H (400 MHz, DMSO) 1.33 (6H, d, J 6.8), 5.11 (1H, m), 7.20 (1H, d, J 6.1), 7.56-7.63 (2H, m), 7.74 (1H, m), 7.61-7.84 (4H, m), 8.06 (1H, dd, J 8.7 and 2.6); m/z (ES⁺) 391 [M+H]⁺; Found C, 68.00; H, 4.04; N, 14.03. C₂₂H₁₆F₄N₄O requires C, 67.79; H, 4.13; N, 14.35%.

EXAMPLE 9

25

3-Chloro-2'-fluoro-5'-(7-methyl-8-oxo-7,8-dihydroimidazo[1,2-α]pyrazin-3-yl)biphenyl-4-carbonitrile

A mixture of 4-bromo-2-chlorobenzonitrile (2.2 g, 10 mmol) and 2-fluorobenzenboronic acid (1.82 g, 13 mmol) in tetrahydrofuran (30 ml) was treated with 2M sodium carbonate (13 ml) then degassed with nitrogen for 10 min. Tetrakis(triphenylphosphine)palladium(0) (0.58 g,

0.5 mmol) was added and this mixture was heated under reflux for 12 h. The resulting mixture was partitioned between dichloromethane and water. The organics were washed with water, brine, dried over anhydrous magnesium sulphate, filtered and concentrated *in vacuo*. Purification of the residue by chromatography on silica gel eluting with isohexane on a gradient of ethyl acetate (5-15%) gave 3-chloro-2'-fluorobiphenyl-4-carbonitrile as a white solid (2.3 g, 99%): δ_{H} (400 MHz, CDCl_3) 7.17-7.57 (5H, m), 7.64-7.75 (2H, m).

To a slurry of 3-chloro-2'-fluorobiphenyl-4-carbonitrile (2.3 g, 10 mmol) and 1,3-dibromo-5,5-dimethylhydantoin (3.1 g, 11 mmol) in acetonitrile (20 ml) was added concentrated sulphuric acid (0.8 ml). The slurry was warmed to 70°C and the resulting solution stirred at 70°C for 16 h. After 16 h, the reaction was complete. Water (75 ml) was added and the resulting suspension was filtered and dried, to give 5'-bromo-3-chloro-2'-fluorobiphenyl-4-carbonitrile as an off-white solid (3.1 g, 98%): δ_{H} (360 MHz, CDCl_3) 7.07-7.17 (1H, m), 7.29-7.76 (5H, m).

5'-Bromo-3-chloro-2'-fluorobiphenyl-4-carbonitrile (0.6 g, 2 mmol), 4,4,5,5,4',4',5',5'-octamethyl-[2,2']bi[[1,3,2]dioxaborolanyl] (0.6 g, 2.4 mmol) and potassium acetate (0.39 g, 4 mmol) were suspended in 1,4-dioxane (6 ml) and the mixture was degassed with nitrogen for 10 minutes, before adding 1,1'-bis(diphenylphosphino)ferrocene-dichloropalladium(II) complex with dichloromethane (0.05 g, 0.06 mmol). The resulting mixture was heated at 90°C for 12 h. The mixture was cooled to ambient temperature, filtered and the filter-cake washed with dichloromethane. The filtrate was evaporated to dryness and the residue stirred with ice-cold 2N sodium hydroxide (70 ml) for 20 minutes. The aqueous mixture was filtered and the filtrate washed with diethyl ether (2 x 50 ml). The organics were discarded and the aqueous phase cooled to 0°C before lowering the pH to 6 by addition of 36% hydrochloric acid. The product was extracted into diethyl ether to give 3-chloro-2'-fluoro-5'-

(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)biphenyl-4-carbonitrile as a yellow oil (0.53 g, 74%).

3-Bromo-7-methyl-7*H*-imidazo[1,2-*a*]pyrazin-8-one and 3-chloro-2'-fluoro-5'-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)biphenyl-4-carbonitrile were coupled in the same way as in Example 5 to give 3-chloro-2'-fluoro-5'-(7-methyl-8-oxo-7,8-dihydroimidazo[1,2-*a*]pyrazin-3-yl)-biphenyl-4-carbonitrile as an off-white solid (50 mg, 26%): δ_H (360 MHz, d_6 -DMSO) 3.48 (3H, s), 7.18 (1H, d, *J* 6), 7.56-7.59 (2H, m), 7.70-7.90 (2H, m), 8.12 (2H, dd, *J* 8 and 3); *m/z* (ES⁺) 379 [M+H]⁺.

EXAMPLE 10

4,2'-Difluoro-5'-[7-(2-fluoroethyl)-8-oxo-7,8-dihydroimidazo[1,2-*a*]pyrazin-3-yl]biphenyl-2-carbonitrile

The title compound was prepared using the method described in Example 6, using 1-bromo-2-fluoroethane instead of iodoethane: δ_H (400 MHz, DMSO) 4.25 (1H, t, *J* 4.5), 4.31 (1H, t, *J* 4.5), 4.65 (1H, t, *J* 4.5), 4.77 (1H, t, *J* 4.5), 7.18 (1H, d, *J* 6.0), 7.59-7.62 (2H, m), 7.74 (1H, m), 7.75-7.85 (4H, m), 8.07 (1H, dd, *J* 8.7 and 2.6); *m/z* (ES⁺) 395 [M+H]⁺; Found C, 63.49; H, 3.27; N, 13.96. C₂₁H₁₃F₃N₄O requires C, 63.96; H, 3.32; N, 14.21%.

EXAMPLE 11

4'-Fluoro-3'-(7-methyl-8-oxo-7,8-dihydroimidazo[1,2-*a*]pyrazin-3-yl)-biphenyl-2-carbonitrile

3-Bromo-7-methyl-7*H*-imidazo[1,2-*a*]pyrazin-8-one and 4'-fluoro-3'-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)biphenyl-2-carbonitrile were coupled in the same way as in Example 5 to give 4'-fluoro-3'-(7-methyl-8-oxo-7,8-dihydroimidazo[1,2-*a*]pyrazin-3-yl)biphenyl-2-carbonitrile as an off-white solid (40 mg, 24%): δ_H (400 MHz, d_6 -DMSO) 3.48 (3H, s), 7.20

(1H, d, *J* 6), 7.43 (1H, dd, *J* 6 and 2), 7.61-7.66 (2H, m), 7.72-7.86 (5H, m), 8.01 (1H, dd, *J* 8 and 1); *m/z* (ES⁺) 345 [M+H]⁺.

EXAMPLE 12

5

5'-Fluoro-3'-(7-methyl-8-oxo-7,8-dihydroimidazo[1,2-*a*]pyrazin-3-yl)-
biphenyl-2-carbonitrile

3-Bromo-7-methyl-7*H*-imidazo[1,2-*a*]pyrazin-8-one and 5'-fluoro-3'-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)biphenyl-2-carbonitrile were
10 coupled in the same way as in Example 5 to give 5'-fluoro-3'-(7-methyl-8-oxo-7,8-dihydroimidazo[1,2-*a*]pyrazin-3-yl)biphenyl-2-carbonitrile as an off-white solid (50 mg, 29%): δ_{H} (400 MHz, *d*₆-DMSO) 3.48 (3H, s), 7.22 (1H, d, *J* 6), 7.59-7.70 (5H, m), 7.79-7.87 (2H, m), 7.80 (1H, s), 8.03 (1H, dd, *J* 8 and 1); *m/z* (ES⁺) 345 [M+H]⁺.

15

EXAMPLE 13

2,2'-Difluoro-5'-(7-methyl-8-oxo-7,8-dihydroimidazo[1,2-*a*]pyrazin-3-yl)-
biphenyl-4-carbonitrile

20 3-Bromo-7-methyl-7*H*-imidazo[1,2-*a*]pyrazin-8-one and 2,2'-difluoro-5'-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)biphenyl-4-carbonitrile (prepared in the same way as in Example 9) were coupled in the same way as in Example 5 to give 2,2'-difluoro-5'-(7-methyl-8-oxo-7,8-dihydroimidazo[1,2-*a*]pyrazin-3-yl)biphenyl-4-carbonitrile as an off-white solid (30
25 mg, 16%): δ_{H} (400 MHz, *d*₆-DMSO) 3.48 (3H, s), 7.18 (1H, d, *J* 6), 7.59-7.61 (2H, m), 7.73 (1H, s), 7.75-7.82 (2H, m), 7.87-7.88 (2H, m), 8.05 (1H, d, *J* 10); *m/z* (ES⁺) 363 [M+H]⁺.

EXAMPLE 14

4,2'-Difluoro-5'-[7-(2,2,2-trifluoroethyl)-8-oxo-7,8-dihydroimidazo[1,2- α]pyrazin-3-yl]biphenyl-2-carbonitrile

5 The title compound was prepared using the method described in Example 6, using 1-iodo-2,2,2-trifluoroethane instead of iodoethane: δ_H (400 MHz, DMSO) 4.90 (2H, q, J 9.2), 7.20 (1H, d, J 6.0), 7.60-7.66 (2H, m), 7.75-7.85 (5H, m), 8.06 (1H, dd, J 8.7 and 2.6); m/z (ES⁺) 431 [M+H]⁺.

EXAMPLE 15

10 4,2'-Difluoro-5'-[7-(2-methyl-2H-[1,2,4]triazol-3-ylmethyl)-8-oxo-7,8-dihydroimidazo[1,2- α]pyrazin-3-yl]biphenyl-2-carbonitrile

15 The title compound was prepared using the method described in Example 6, using 3-chloromethyl-2-methyl-2H-[1,2,4]triazole instead of iodoethane: δ_H (400 MHz, DMSO) 3.96 (3H, s), 5.35 (2H, s), 7.28 (1H, d, J 6.0), 7.62-7.64 (2H, m), 7.75-7.84 (6H, m), 8.06 (1H, dd, J 8.6 and 2.7); m/z (ES⁺) 444 [M+H]⁺; Found C, 62.48; H, 3.67; N, 21.98. C₂₃H₁₅F₂N₇O requires C, 62.30; H, 3.41; N, 22.11%.

EXAMPLE 16

20 3-[4-Fluoro-3-(1-methyl-1H-[1,2,3]triazol-4-ylmethoxy)phenyl]-7-methyl-7H-imidazo[1,2- α]pyrazin-8-one

25 A cooled (-20°C) solution of 2,2,6,6-tetramethylpiperidine (28 ml, 165 mmol) in tetrahydrofuran (400 ml) was treated with *n*-butyllithium (63 ml of a 2.5M solution in hexanes, 157.5 mmol). This mixture was then cooled to -78°C. 1-Bromo-4-fluorobenzene (16.5 ml, 150 mmol) was then added neat and dropwise over 10 min and stirring at -78°C was continued
30 for 3 h. Triisopropyl borate (40 ml, 172.5 mmol) was then added and stirring at -78°C continued for 30 min before removing the cooling bath.

When the internal temperature of the reaction reached -40°C , 5N hydrochloric acid was added (75 ml) and the mixture was stirred to ambient temperature. After stirring at ambient temp for 1 h the majority of the tetrahydrofuran was removed and the mixture partitioned between ether (500 ml) and 1N hydrochloric acid (500 ml). The organics were then extracted with 2N sodium hydroxide (400 ml) and the organics were discarded. The aqueous was cooled in an ice-water bath and 5N hydrochloric acid (150 ml) was added dropwise over 15 min. The resulting white solid was collected and dried under vacuum to afford 5-bromo-2-fluorobenzenboronic acid (25 g, 76%).

A solution of 5-bromo-2-fluorobenzenboronic acid (25 g, 114 mmol) in tetrahydrofuran was treated with hydrogen peroxide (7.8 ml of a 35 wt % solution in water) then with sodium hydroxide (1.4 ml of a 4N solution in water). A mild exotherm caused the internal temperature to reach 40°C . This mixture was left to stir at ambient temperature for 14 h then treated with manganese dioxide (200 mg) and stirring was continued for 90 min before filtering the reaction (GF/A filter paper). The filtrate was concentrated on a rotary evaporator and the residue partitioned between ether (400 ml) and water. The organics were washed with more water, brine and dried over anhydrous magnesium sulphate. Filtration and evaporation to dryness afforded 5-bromo-2-fluorophenol (19.7 g, 90%) as a colourless liquid: δ_{H} (400 MHz, d_6 -DMSO) 6.93-6.97 (1H, m), 7.09-7.14 (2H, m), 10.36 (1H, br).

An ice-cooled solution of 5-bromo-2-fluorophenol (1.91 g, 10 mmol), (1-methyl-1H-[1,2,3]triazol-4-yl)methanol (1.24 g, 11 mmol) and triphenylphosphine (3.93 g, 15 mmol) in tetrahydrofuran (50 ml) was treated dropwise with diisopropyl azodicarboxylate (3.03 g, 15 mmol) over 10 min. The resulting mixture was stirred to ambient temperature over 12 h and then glacial acetic acid (1 ml) was added. The reaction mixture was concentrated *in vacuo* then partitioned between ethyl acetate and 0.01N sodium hydroxide solution. The organics were washed with water,

brine, dried over anhydrous magnesium sulphate and concentrated to give an oil. This oil was purified by chromatography on silica gel eluting with isohexane on a gradient of ethyl acetate (20-50%). Product-containing fractions were concentrated and the resulting residue triturated with 10% ether in isohexane to furnish 4-(5-bromo-2-fluorophenoxymethyl)-1-methyl-1*H*-[1,2,3]triazole as a white solid (1.9 g, 66%): δ_H (360 MHz, d_6 -DMSO) 4.06 (3H, s), 5.25 (2H, s), 7.10-7.20 (2H, m), 7.55-7.70 (1H, m), 8.19 (1H, s).

4-(5-Bromo-2-fluorophenoxymethyl)-1-methyl-1*H*-[1,2,3]triazole was converted to 4-fluoro-3-(1-methyl-1*H*-[1,2,3]triazol-4-ylmethoxy)benzeneboronic acid as described in Example 9: δ_H (400 MHz, d_6 -DMSO) 4.06 (3H, s), 5.19 (2H, s), 7.16 (1H, dd, J 12 and 8), 7.38-7.41 (1H, m), 7.71 (1H, dd, J 9 and 1), 8.09 (2H, s), 8.16 (1H, s).

3-Bromo-7-methyl-7*H*-imidazo[1,2-*a*]pyrazin-8-one and 4-fluoro-3-(1-methyl-1*H*-[1,2,3]triazol-4-ylmethoxy)benzeneboronic acid were coupled as described in Example 9 to afford 3-[4-fluoro-3-(1-methyl-1*H*-[1,2,3]triazol-4-ylmethoxy)phenyl]-7-methyl-7*H*-imidazo[1,2-*a*]pyrazin-8-one as a white solid: δ_H (400 MHz, d_6 -DMSO) 3.48 (3H, s), 4.06 (3H, s), 5.35 (2H, s), 7.17-7.21 (2H, m), 7.39 (1H, dd, J 11 and 8), 7.55 (1H, d, J 6), 7.60 (1H, dd, J 8 and 2), 7.67 (1H, s), 8.22 (1H, s); m/z (ES^+) 355 [$M+H$] $^+$.

EXAMPLE 17

3-[4-Fluoro-3-(2-methyl-2*H*-[1,2,4]triazol-3-ylmethoxy)phenyl]-7-methyl-7*H*-imidazo[1,2-*a*]pyrazin-8-one

A cooled (0°C) solution of 5-bromo-2-fluorophenol, (2-methyl-2*H*-[1,2,4]triazol-3-yl)methanol and triphenylphosphine in tetrahydrofuran was treated dropwise with diisopropyl azodicarboxylate over 10 min. The resulting mixture was stirred overnight and then acetic acid was added. The reaction mixture was evaporated to dryness and the residue was partitioned between ethyl acetate and 0.01N sodium hydroxide solution.

The organic phase was washed with water and brine, dried over anhydrous magnesium sulphate and pre-adsorbed onto silica. Purification by flash column chromatography on silica gel, eluting with isohexane on a gradient of ethyl acetate (10-50%), led to product-containing fractions that were combined. The material was further purified by flash column chromatography on silica gel, eluting with dichloromethane containing 1% ammonia on a gradient of methanol (0.5-3%), to give 5-(5-bromo-2-fluorophenoxymethyl)-1-methyl-1*H*-[1,2,4]triazole as an off-white solid (2.1 g, 37%): δ_H (360 MHz, CDCl₃) 4.01 (3H, s), 5.29 (2H, s), 6.96-6.99 (1H, m), 7.09-7.13 (1H, m), 7.29 (1H, dd, *J* 5 and 2), 7.88 (1H, s); *m/z* (ES⁺) 288 [MH⁺].

5-(5-Bromo-2-fluorophenoxymethyl)-1-methyl-1*H*-[1,2,4]triazole was reacted with 4,4,5,5,4',4',5',5'-octamethyl-[2,2']bi[[1,3,2]-dioxaborolanyl] as described in Example 9 to give 4-fluoro-3-(2-methyl-2*H*-[1,2,4]triazol-3-ylmethoxy)benzeneboronic acid as a pale yellow solid (0.43 g, 62%).

3-Bromo-7-methyl-7*H*-imidazo[1,2-*a*]pyrazin-8-one and 4-fluoro-3-(2-methyl-2*H*-[1,2,4]triazol-3-ylmethoxy)benzeneboronic acid were coupled in the same way as in Example 5 to give 3-[4-fluoro-3-(2-methyl-2*H*-[1,2,4]triazol-3-ylmethoxy)phenyl]-7-methyl-7*H*-imidazo[1,2-*a*]pyrazin-8-one as a white solid (58 mg, 33%): δ_H (400 MHz, d₆-DMSO) 3.48 (3H, s), 3.94 (3H, s), 5.52 (2H, s), 7.21-7.25 (2H, m), 7.45 (1H, dd, *J* 11 and 8), 7.53 (1H, d, *J* 6), 7.62 (1H, dd, *J* 8 and 2), 7.65 (1H, s), 7.98 (1H, s); *m/z* (ES⁺) 355 [M+H]⁺.

25

EXAMPLE 18

7-Ethyl-3-[4-fluoro-3-(2-methyl-2*H*-[1,2,4]triazol-3-ylmethoxy)phenyl]-7*H*-imidazo[1,2-*a*]pyrazin-8-one

3-Bromo-7-ethyl-7*H*-imidazo[1,2-*a*]pyrazin-8-one and 4-fluoro-3-(2-methyl-2*H*-[1,2,4]triazol-3-ylmethoxy)benzeneboronic acid were coupled in the same way as in Example 5 to give 7-ethyl-3-[4-fluoro-3-(2-methyl-2*H*-

[1,2,4]triazol-3-ylmethoxy)phenyl]-7*H*-imidazo[1,2-*a*]pyrazin-8-one as a white solid (43 mg, 23%): δ_H (400 MHz, d_6 -DMSO) 1.26 (3H, t, *J* 7), 3.94 (3H, s), 3.96 (2H, s), 5.52 (2H, s), 7.22-7.26 (2H, m), 7.44 (1H, dd, *J* 11 and 8), 7.55 (1H, d, *J* 6), 7.64 (1H, dd, *J* 8 and 2), 7.66 (1H, s), 7.98 (1H, s); *m/z* (ES⁺) 369 [M+H]⁺.

EXAMPLE 19

10 4,2'-Difluoro-5'-[8-oxo-7-(pyridin-2-ylmethyl)-7,8-dihydroimidazo[1,2-*a*]pyrazin-3-yl]biphenyl-2-carbonitrile

The title compound was prepared using the method described in Example 6, using 2-chloromethylpyridine hydrochloride instead of iodoethane: δ_H (400 MHz, DMSO) 5.26 (2H, s), 7.28-7.35 (3H, m), 7.61-7.63 (2H, m), 7.76-7.86 (6H, m), 8.06 (1H, dd, *J* 8.6 and 2.7), 8.50 (1H, m); *m/z* (ES⁺) 440 [M+H]⁺; Found C, 68.19; H, 3.48; N, 15.69. C₂₅H₁₅F₂N₅O requires C, 68.33; H, 3.44; N, 15.94%.

EXAMPLE 20

20 4,2'-Difluoro-5'-(7-methyl-8-oxo-5,6,7,8-tetrahydroimidazo[1,2-*a*]pyrazin-3-yl)biphenyl-2-carbonitrile

A suspension of 8-chloroimidazo[1,2-*a*]pyrazine (5 g, 325 mmol) in 5N hydrochloric acid (35 ml) was heated at 90°C for 14 h. The reaction mixture was cooled, then concentrated using rotary evaporation. Azeotropic removal of water with toluene (2 x 30 ml) gave 8-oxo-7,8-dihydroimidazo[1,2-*a*]pyrazine hydrochloride (5.7 g): δ_H (360 MHz, DMSO) 7.01 (1H, d, *J* 5.6), 7.60 (1H, d, *J* 5.6), 7.70 (1H, s), 7.97 (1H, s), 11.59 (1H, br s).

8-Oxo-7,8-dihydroimidazo[1,2-*a*]pyrazine hydrochloride (1 g) was suspended in *N,N*-dimethylformamide (15 ml) then treated with sodium hydride (650 mg of a 60% dispersion in mineral oil). The resulting mixture

was heated at 60°C for 20 min then cooled to room temperature and treated with iodomethane (0.4 ml). After stirring for 15 h the reaction mixture was diluted cautiously with methanol (5 ml) and then silica gel (5 g) was added and the solvents removed under vacuum. The silica residue
5 was filtered through a plug of silica gel, using 10% methanol in dichloromethane as eluent, then the solvents were removed *in vacuo* to leave 7-methyl-7*H*-imidazo[1,2-*a*]pyrazin-8-one (1.15 g): δ_{H} (360 MHz, DMSO) 3.43 (3H, s), 7.11 (1H, d, *J* 5.8), 7.46 (1H, s), 7.56 (1H, d, *J* 5.8), 7.78 (1H, s). NOE studies showed that irradiation of the 3H singlet at δ
10 3.43 gave enhancement of the doublet at δ 7.11 and vice-versa indicating that methylation took place on the 7-nitrogen rather than the 8-oxygen.

7-Methyl-7*H*-imidazo[1,2-*a*]pyrazin-8-one (315 mg, 2.1 mmol) in a Parr flask was dissolved in methanol (20 ml) and 10% Pd-C catalyst (100 mg) was added. The reaction mixture was shaken under 55 psi of
15 hydrogen for 16 days then filtered and concentrated under vacuum to leave a residue. This was recrystallized from ethyl acetate/methanol to give 7-methyl-8-oxo-5,6,7,8-tetrahydroimidazo[1,2-*a*]pyrazine (185 mg): δ_{H} (360 MHz, DMSO) 3.31 (3H, s), 3.70-3.73 (2H, m), 4.24-4.28 (2H, m), 7.08 (1H, s), 7.32 (1H, s).

20 7-Methyl-8-oxo-5,6,7,8-tetrahydroimidazo[1,2-*a*]pyrazine (80 mg, 0.53 mmol) and 5'-bromo-4,2'-difluorobiphenyl-2-carbonitrile (prepared as described in WO 02/074773, 204 mg, 1.3 mol. eq) were dissolved in DMA (2 ml) and potassium acetate (280 mg, 1.5 mol eq), palladium acetate (6 mg, 5 mol %) and triphenylphosphine (7 mg, 5 mol %) were all added. After
25 bubbling nitrogen through the reaction mixture for 10 min, the temperature was raised to 130°C and heating continued for 3 h. After cooling, the crude reaction mixture was poured onto a column of silica and purified using 0-5% methanol in dichloromethane as eluent.

Recrystallization from ethyl acetate/dichloromethane gave the title
30 compound (18 mg), mp 224°C: δ_{H} (400 MHz, DMSO) 3.02 (3H, s), 3.72-3.75

(2H, m), 4.35-4.38 (2H, m), 7.38 (1H, s), 7.57 (1H, m), 7.72-7.78 (4H, m), 8.06 (1H, dd, *J* 9 and 3); *m/z* (ES⁺) 365 [M+H]⁺.

EXAMPLE 21

5

4,2'-Difluoro-5'-(7-ethyl-8-oxo-5,6,7,8-tetrahydroimidazo[1,2-*a*]pyrazin-3-yl)biphenyl-2-carbonitrile

8-Oxo-7,8-dihydroimidazo[1,2-*a*]pyrazine hydrochloride (see Example 20, 1 g) in a Parr flask was dissolved in methanol (60 ml) and 10% Pd-C catalyst (300 mg) was added. The reaction mixture was shaken under 55 psi of hydrogen for 17 days then filtered and concentrated under vacuum to leave a residue. This was recrystallized from ethyl acetate/methanol to give 8-oxo-5,6,7,8-tetrahydroimidazo[1,2-*a*]pyrazine hydrochloride (610 mg): δ_{H} (360 MHz, DMSO) 3.66-3.70 (2H, m), 4.36-4.39 (2H, m), 7.67 (1H, s), 7.78 (1H, s), 8.84 (1H, br s).

8-Oxo-5,6,7,8-tetrahydroimidazo[1,2-*a*]pyrazine hydrochloride (500 mg, 40 mmol) was suspended in *N,N*-dimethylformamide (10 ml) then treated with sodium hydride (380 mg of a 60% dispersion in mineral oil, 2.4 mol eq). The resulting mixture was heated at 60°C for 20 min then cooled to room temperature and treated with iodoethane (0.386 ml, 1.2 mol eq). After stirring for 15 h the reaction mixture was diluted cautiously with methanol (5 ml) and then silica gel (4 g) was added and the solvents removed under vacuum. The silica residue was filtered through a plug of silica gel, using 10% methanol in dichloromethane as eluent, then the solvents were removed *in vacuo* to leave 7-ethyl-8-oxo-5,6,7,8-tetrahydroimidazo[1,2-*a*]pyrazine (400 mg): δ_{H} (400 MHz, DMSO) 1.10 (3H, t, *J* 7.2), 3.47 (2H, *J* 7.2), 3.70-3.73 (2H, m), 4.23-4.27 (2H, m), 7.08 (1H, s), 7.32 (1H, s).

7-Ethyl-8-oxo-5,6,7,8-tetrahydroimidazo[1,2-*a*]pyrazine (82.5 mg, 0.53 mmol) and 5'-bromo-4,2'-difluorobiphenyl-2-carbonitrile (prepared as described in WO 02/074773, 204 mg, 1.3 mol eq) were dissolved in DMA (2

ml) and potassium acetate (280 mg, 1.5 mol eq), palladium acetate (6 mg, 5 mol %) and triphenylphosphine (7 mg, 5 mol %) were all added. After bubbling nitrogen through the reaction mixture for 10 min, the temperature was raised to 130°C and heating continued for 3 h. After cooling, the crude reaction mixture was poured onto a column of silica and purified using 0-5% methanol in dichloromethane as eluent. Recrystallization from ethyl acetate/dichloromethane gave the title compound (18 mg): δ_H (400 MHz, DMSO) 1.12 (3H, t, J 7.1), 3.51 (2H, q, J 7.1), 3.73-3.76 (2H, m), 4.34-4.37 (2H, m), 7.39 (1H, s), 7.57 (1H, m), 7.72-7.78 (4H, m), 8.06 (1H, dd, J 9 and 3); m/z (ES⁺) 379 [M+H]⁺.

EXAMPLE 22

5,2'-Difluoro-5'-(7-ethyl-8-oxo-5,6,7,8-tetrahydroimidazo[1,2- α]pyrazin-3-yl)biphenyl-2-carbonitrile

This compound was prepared in the same way as described in Example 21 but replacing 5'-bromo-4,2'-difluorobiphenyl-2-carbonitrile with 5'-bromo-5,2'-difluorobiphenyl-2-carbonitrile (prepared as described in WO 02/074773): δ_H (400 MHz, DMSO) 1.11 (3H, t, J 7.1), 3.51 (2H, q, J 7.1), 3.73-3.76 (2H, m), 4.35-4.38 (2H, m), 7.40 (1H, s), 7.55-7.61 (2H, m), 7.68-7.78 (3H, m), 8.13 (1H, dd, J 9 and 3); m/z (ES⁺) 379 [M+H]⁺.

EXAMPLE 23

6,2'-Difluoro-5'-(7-ethyl-8-oxo-5,6,7,8-tetrahydroimidazo[1,2- α]pyrazin-3-yl)biphenyl-2-carbonitrile

This compound was prepared in the same way as described in Example 21 but replacing 5'-bromo-4,2'-difluorobiphenyl-2-carbonitrile with 5'-bromo-6,2'-difluorobiphenyl-2-carbonitrile (prepared as described in WO 02/074773): δ_H (400 MHz, DMSO) 1.20 (3H, t, J 7.1), 3.59 (2H, q, J

7.1), 3.82-3.85 (2H, m), 4.39-4.45 (2H, m), 7.45 (1H, s), 7.65-7.70 (1H, m), 7.83-7.92 (4H, m), 8.00 (1H, dd, *J* 9 and 3); *m/z* (ES⁺) 379 [M+H]⁺.

EXAMPLE 24

5

6,2'-Difluoro-5'-(7-methyl-8-oxo-7,8-dihydroimidazo[1,2-*a*]pyrazin-3-yl)-biphenyl-2-carbonitrile

This compound was prepared in the same way as described in Example 5 except replacing 4,2'-difluoro-5'-(5,5-dimethyl-
10 [1,3,2]dioxaborinan-2-yl)biphenyl-2-carbonitrile with 6,2'-difluoro-5'-(5,5-dimethyl-[1,3,2]dioxaborinan-2-yl)biphenyl-2-carbonitrile in the final step:
 δ_{H} (400 MHz, CDCl₃) 3.59 (3H, s), 6.71 (1H, d, *J* 6.0), 7.37-7.67 (8H, m); *m/z* (ES⁺) 363 [M+H]⁺.

15

EXAMPLE 25

6,2'-Difluoro-5'-(7-ethyl-8-oxo-7,8-dihydroimidazo[1,2-*a*]pyrazin-3-yl)-biphenyl-2-carbonitrile

This compound was prepared in the same way as described in
20 Example 6 except replacing 4,2'-difluoro-5'-(5,5-dimethyl-[1,3,2]dioxaborinan-2-yl)biphenyl-2-carbonitrile with 6,2'-difluoro-5'-(5,5-dimethyl-[1,3,2]dioxaborinan-2-yl)biphenyl-2-carbonitrile in the final step:
 δ_{H} (400 MHz, CDCl₃) 1.38 (3H, t, *J* 7.1), 4.04 (2H, q, *J* 7.1), 6.72 (1H, d, *J* 6.0), 7.38-7.67 (8H, m); *m/z* (ES⁺) 377 [M+H]⁺.

25

EXAMPLE 26

5,2'-Difluoro-5'-(7-methyl-8-oxo-5,6,7,8-tetrahydroimidazo[1,2-*a*]pyrazin-3-yl)biphenyl-2-carbonitrile

30

The title compound was prepared in the same way as described in Example 20 except replacing 5'-bromo-4,2'-difluorobiphenyl-2-carbonitrile

with 5'-bromo-5,2'-difluorobiphenyl-2-carbonitrile in the final step: δ_H (400 MHz, $CDCl_3$) 3.18 (3H, s), 3.75-3.77 (2H, m), 4.32-4.34 (2H, m), 7.24-7.28 (1H, m), 7.30-7.38 (3H, m), 7.44-7.46 (1H, m), 7.52-7.55 (1H, m), 7.83 (1H, dd, J 7 and 4); m/z (ES⁺) 365 [M+H]⁺.

5

EXAMPLE 27

4,2'-Difluoro-5'-[8-oxo-7-(pyridin-2-ylmethyl)-5,6,7,8-tetrahydroimidazo[1,2- α]pyrazin-3-yl]biphenyl-2-carbonitrile

10 8-Oxo-5,6,7,8-tetrahydroimidazo[1,2- α]pyrazine hydrochloride (87 mg, 0.53 mmol), prepared as described in Example 21, was reacted with 5'-bromo-4,2'-difluorobiphenyl-2-carbonitrile (prepared as described in WO 02/074773, 204 mg, 1.3 mol eq) in DMA (2 ml) in the presence of potassium acetate (280 mg, 1.5 mol eq), palladium acetate (6 mg, 5 mol %) and
15 triphenylphosphine (7 mg, 5 mol %). After bubbling nitrogen through the reaction mixture for 10 min, the temperature was raised to 130°C and heating continued for 3 h. After cooling, the crude reaction mixture was poured onto a column of silica and purified using 0-5% methanol in dichloromethane as eluent. Recrystallization from ethyl acetate/
20 dichloromethane gave 4,2'-difluoro-5'-(8-oxo-7,8-dihydroimidazo[1,2- α]pyrazin-3-yl)biphenyl-2-carbonitrile (126 mg): δ_H (400 MHz, DMSO) 3.54-3.58 (2H, m), 4.28-4.32 (2H, m), 7.39 (1H, s), 7.54-7.59 (1H, m), 7.71-7.78 (4H, m), 8.05-8.08 (1H, m), 8.18 (1H, br s); m/z (ES⁺) 351 [M+H]⁺.

25 The title compound was prepared using the method described in the first part of Example 6, using 2-chloromethylpyridine hydrochloride instead of iodoethane: δ_H (400 MHz, DMSO) 3.60-3.64 (2H, m), 4.18-4.22 (2H, m), 4.60 (2H, m), 7.08-7.11 (1H, m), 7.16-7.19 (1H, m), 7.21 (1H, s), 7.54-7.59 (1H, m), 7.52-7.56 (5H, m), 7.82-7.86 (1H, m), 8.30-8.32 (1H, m); m/z (ES⁺) 442 [M+H]⁺.

30

EXAMPLE 28


6,2'-Difluoro-5'-(7-methyl-8-oxo-5,6,7,8-tetrahydroimidazo[1,2- α]pyrazin-3-yl)biphenyl-2-carbonitrile

5 The title compound was prepared in the same way as described in
Example 20 except replacing 5'-bromo-4,2'-difluorobiphenyl-2-carbonitrile
with 5'-bromo-6,2'-difluorobiphenyl-2-carbonitrile in the final step: δ_H (400
MHz, $CDCl_3$) 3.19 (3H, s), 3.73-3.78 (2H, m), 4.28-4.35 (2H, m), 7.34-7.42
(3H, m), 7.45-7.49 (1H, m), 7.54-7.58 (2H, m), 7.64 (1H, m); m/z (ES^+) 365
10 [M+H] $^+$.

THIS PAGE BLANK (USPTO)

PCT Application

GB0304685



**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.